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 I Abstract 
Alterations in the local chromatin structure orchestrate the dynamic regulation of 
differentiation promoting genes. PU.1 is a master transcription factor in hematopoiesis. PU.1 
gene must be tightly regulated to achieve lineage specific expression pattern. High levels of 
PU.1 are required for myeloid commitment: it is expressed at intermediate level in B-cells and 
must be actively silenced to permit T cell development from early multipotent progenitors. 
However, little is known of how PU.1 is regulated in T-cells. Moreover, aberrant PU.1 
expressions have been observed in multiple leukemias.  
Using a genome-wide chromatin interaction screen we identified a cis-repressor with 
insulating capacity that undergoes long-distant chromatin looping to block PU.1 promoter 
activity in T cells but not myeloid or B cells. Looping and repression requires binding of the 
chromatin regulator protein CTCF. In contrast to normal myeloid cells, we found that cancer 
cells from myeloid leukemia patients adopt the T cell specific repressive chromatin structure 
bringing the insulator into spatial contact with the PU.1 promoter. These results identify 
CTCF controlled long-distant insulator looping as a novel mechanism to silence lineage-
opposing transcription factor expression, and reveal that cancer cells can mimic the chromatin 
confirmation of another lineage to block expression of differentiation driving genes.  
 
Keywords: PU.1, hematopoiesis, chromatin conformation, gene regulation, leukemia
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 II Zusammenfassung 
Veränderungen  in der lokalen Chromatinstruktur beeinflussen die dynamische Regulation 
von Genen, welche für die Differenzierung notwendig sind. PU.1 ist ein Master-
Transkriptionsfaktor in der Hämatopoese und wird streng reguliert, um ein 
zelllinienspezifisches  Expressionsmuster zu erzielen. Hohe Konzentrationen von PU.1 sind 
für myeloische Differenzierung erforderlich. In B-Zellen wird PU.1 mittelstark exprimiert und 
muss aktiv runterreguliert werden, um eine Ausdifferenzierung der multipotenten 
Vorläuferzellen zu T-Zellen zu ermöglichen. Derzeit ist wenig über die Regulierung von PU.1 
in T-Zellen bekannt. Darüber hinaus wurde eine abnormale Expression von PU.1 in 
verschiedenen Leukämieerkrankungen beobachtet. 
Mittels eines genome-wide Chromatin-Interaktions-Screens konnten wir einen cis-Repressor 
mit insulierender Kapazität identifizieren, welcher mittels eines Chromatinloops die 
Promotoraktivität von PU.1 in T-Zellen, jedoch nicht in myeloischen oder B-Zellen blockiert. 
Sowie Looping als auch Insulation erfordern die Bindung des Chromatin-Regulatorprotein 
CTCF. Im Gegensatz zu normalen myeloischen Zellen finden wir, dass Krebszellen aus 
myeloischen Leukämie Patienten diese T-Zell-spezifische repressive Chromatinstruktur 
aufweisen, was einen räumlichen Kontakt des Insulator mit dem PU.1 Promotor ermöglicht. 
Die Ergebnisse dieser Arbeit beschrieben das CTCF gesteuerte „long distance looping“ als ein 
neuer molekularer epigenetischer Mechanismus, um Transkriptionsfaktor PU.1 in T-Zellen 
runterzuregulieren, und zeigen zum ersten mal, dass Krebszellen die Chromatinstruktur 
anderer Zelllinien imitieren können, um die Expression von Differenzierungsgenen zu 
blockieren. 
 
Schlagwörter: PU.1, Hämatopoiesis, Chromatin Struktur, Generegulation, Läukemie
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1 Introduction 
1.1 Gene regulation 
After the sequencing of the human genome had been essentially completed in 2001 (Lander et 
al., 2001; McPherson et al., 2001), the gene-centric paradigm shifted eventually to a genome-
wide investigation, finally confirming the presence of gene networks, which define the 
effective transcriptome of specific cell populations (McPherson et al., 2001; Zhou et al., 
2011). Moreover, comparative genome analysis revealed a surprisingly constancy in genetic 
content: vertebrate genomes contain only about twice the number of genes compared to 
invertebrate ones. Hence, evolutionary diversity can not be explained by the number of genes. 
Emerging evidences suggest that organisms’ complexity developed due to a progressively 
elaborated gene regulation.  
Hence, transcriptional regulation of genes is a tightly coordinate process which involves trans-
acting proteins (transcription factors), binding at different genomic regions to modulate the 
transcriptional activity of a certain gene, binding on promoters and cis-regulatory elements in 
a chromatin-dependent context (discussed in the next chapter). 
1.1.1 Trans-acting factors 
Gene regulation is controlled by cis and trans- acting factors.  
An enlightening example in this perspective is an increased absolute number of transcription 
factors (TF) (around 3000 in human, 300 in yeast) as well in the ratio of transcription factors 
per genome (1 per 10 genes in human; 1 per 20 in yeast) and their combinatorial activity on 
gene regulation (Levine and Tjian, 2003). This underlies the importance of trans-acting 
transcription factors as one of the driving force of the transcriptional decision-making. Not 
surprisingly, TF are involved in transcriptional regulation of genes coding for protein 
involved in every biological process. TF rarely act alone for a single cellular response; their 
function is rather a coordinate action of TF networks.  
Perturbation of these networks can lead to neoplastic transformation resulting in cancer. Next-
generation sequencing (NGS) methods allow nowadays to obtain an overview of gene 
expression on the genome wide level, however it is still challenging to analyze  binding and 
function of multiple TF in different cell type (cancer cells compared to normal controls), due 
to huge bioinformatics work and lack of appropriate controls and algorithms. Therefore, it is 
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important to dissect gene regulation of a single TF by genetic manipulation integrated with 
molecular biology to understand in detail the contribution of a specific TF into different 
networks (Wilson et al., 2011a). 
1.1.2 Cis-acting factors 
1.1.2.1 Promoters 
The promoter of a gene consists in general of two regions: the core-promoter and the 
proximal-promoter. The core-promoter is canonically characterized by the presence of the 
TATA box, located upstream of the transcriptional start site (TSS) Basal transcription 
machinery, including the TF-II family transcription factors, binds to the TATA box recruiting 
the RNA-polymerase II, which transcribes the gene (Smale and Kadonaga, 2003). However, 
only 32% of potential core-promoters in the human genome contain a standard TATA-box, 
the majority of which are housekeeping genes (Suzuki et al., 2001). The rest of promoters are 
regulated by the proximal region. The proximal promoter sequences are adjacent to the 
eventual core-promoter and display multiple TF binding sites which coordinate the 
recruitment of the transcriptional factory (RNAPII and related cofactors).  
1.1.2.2 Enhancers and silencers 
Enhancers are cis-elements which influence the transcription of specific genes, by recruiting 
the transcriptional machinery (RNAPII and cofactors), transcription factors and chromatin 
regulators to distal promoters, therefore inducing gene expression. Enhancers can be located 
upstream or downstream the gene promoter, in intronic regions or non-coding ones; hence, 
their function is independent from their orientation and spatial location (Suzuki et al., 2001; 
Atchison, 1988). Enhancers do not contain particular DNA sequences as signature, but 
binding sites of chromatin remodelers and transcription factors determine the specificity of 
their action on a particular gene and in a particular cell context (Majumder et al., 1997). 
Histone modification profiles (see next chapter) have been very useful to globally characterize 
enhancers. Recently, by genome-wide screening of histone modifications (see next chapter), 
Heintzman and colleagues (Heintzman et al., 2007) identified H3K4me1 (monomethylated 
lysine 4 on histon 3) as chromatin signature of enhancers in human and mouse genomes.  
It remains unclear how enhancers function. There are two current theories: contact and no-
contact models. The last one hypothesizes that enhancers indirectly modify the state of the 
respective promoter by changing the accessibility of promoter sequences to transcriptional 
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factories. The contact model proposes a physical interaction between promoter and enhancer, 
resulting in a chromatin loop (Zhou et al., 2011).  
Silencers are cis-acting element as well, and their function and properties are very similar to 
enhancers, with the difference of the final outcome: when they are activated by transcription 
factors, the transcriptional activity of the relevant gene is reduced or blocked. 
Silencers and enhancers are often located in a proximity to each other, and sometimes they 
overlap, assuming different functions in diferent cell type context. A clear example is 
represented by the cluster of regulatory element upstream the promoter of the transcription 
factor PU.1, as explained in chapter 1.4.1. In vertebrate, the majority of genes is regulated by 
a balance of different elements. This complex regulation is even more profound in genes 
encoding for transcription factors, which role is crucial in early differentiation programs, as 
the best known triad oct4, Sox2, Nanog (Wernig et al., 2007) for embryonic stem cells, or the 
complex network of hematopoietic factors (Rosenbauer and Tenen, 2007). 
1.1.2.3 Insulators 
A third category of regulatory element is represented by insulators. Their discovery is very 
recent compared to the other cis-acting elements: in 1999 Bell and colleagues described, and 
named (Bell et al., 1999), the first insulator. Insulators delimit independent transcriptional 
domains in eukaryotic genome (Bell and Felsenfeld, 2000; Bell et al., 2001). They are 
traditionally divided in two categories: barriers insulators and enhancer blocking ones (Bell et 
al., 1999; Gaszner and Felsenfeld, 2006).  Barrier insulators are proposed to shield active 
genes from heterochromatin spreading (and consequent transcriptional silencing), by 
recruiting protein complexes that create a sterical obstruction (Felsenfeld et al., 2004; Litt et 
al., 2001). Enhancer blocking insulators shield a promoter from an enhancer’s action. 
Importantly, these insulators are required to be physically located between the respective 
promoter and enhancers, in other words, they are position dependent. In eukaryotes, both 
types of insulator are prevalently bound by CTCF protein (see next chapter), which mediate 
their function in cooperation with multiple partner (Wallace and Felsenfeld, 2007). 
The molecular mechanism underlying insulators’ function remains elusive. Possible 
mechanisms might include sterical effect(Bell et al., 1999), a role in modifying chromatin by 
recruiting chromatin remodelers (Ishihara et al., 2006; Han et al., 2008) and also involvement 
of no coding RNA in gene transcription (Grimaud et al., 2006; Lei and Corces, 2006).  
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Figure 1: Cis-acting elements regulate transcriptional activity of respective genes. The picture illustrated 
the three categories of regulatory elements mentioned in the main text, a) enhancer, b) silencer, c) insulator. As 
the words suggest, the enhancer affects positively the transcription of the respective gene; the silencer plays the 
opposite role; the insulator constitutes a barrier between different gene loci so that regulatory elements specific 
for one gene don’t affect also the neighbor’s ones. 
1.2 Epigenetic: chromatin structure and their organizers 
The term “epigenetics” was first coined by Conrad H. Waddington in 1942 as a fusion of the 
words genetics and epigenesis describing “the branch of biology which studies the causal 
interactions between genes and their products, which bring the phenotype into being” 
(Waddington, 2012). In other words, it is a field that describes changes in a cellular phenotype 
that are independent of alterations in the DNA sequence, thus representing a global 
connection from genotype to phenotype. In the last 50 years, several processes has been 
explained by epigenetic mechanism: for instance  imprinting genes (Ohlsson, 2007; McGrath 
and Solter, 1984; LYON, 1961) and X chromosome inactivation in vertebrates, which will be 
not further commented since they are out of scope of this thesis. Hereafter a summary of 
chromatin organization will be given, with a particular focus on chromatin organizers 
involved in this study.  
1.2.1 Chromatin organization 
In eukaryotic cells DNA is packaged repetitively in nucleosomes by interaction with histone 
proteins. One nucleosome is an octamer of histones (twice each H2A, H2B, H3 and H4) 
wrapped by 147bp of DNA (Olins and Olins, 1974; Luger et al., 1997). Nucleosome is a 
fundamental unit of chromatin. Its positioning along with DNA modifications and histone tail 
variants refers to the primary structure of chromatin. A higher level of chromatin organization 
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is the high-order structure and nuclear compartmentalization, together leading to the 
definition of three-dimensional structure of the nucleus (Olins and Olins, 1974; Richmond 
and Davey, 2003).  
1.2.2 DNA modifications 
DNA methylation, apart from the just recently discovered 5-hydroxymethylcytosine 
(Kriaucionis and Heintz, 2009; Tahiliani et al., 2009), is the only known covalent 
modification of DNA in mammals. DNA methylation is achieved by the addiction of a methyl 
group to the C5 of the cytosine – it is a very general mechanism and that is found in 
prokaryotes and eukaryotes (Bird, 1980). In eukaryotes, DNA methylation occurs prevalently 
on the cytosine in the context of CpG dinucleotide. This DNA modification is usually 
associated with inhibition of transcription, therefore is considered to be a repressive mark. Its 
function is achieved by displacement of transcription factor from its binding site in case of 
methylation-sensitive DNA binding or affecting the chromatin status around the promoter of a 
gene. Interestingly, in cancer DNA methylation pattern is not randomly altered (Costello et 
al., 2000), contributing to a tumor-type specific aberrant transcriptional program.   
1.2.3 Histon modifications 
In 1964 Allfrey proposed that post-translational modifications of histones play a role in 
transcriptional regulation of genes (ALLFREY et al., 1964). However, this theory was 
reconsidered only 20 years after (Weintraub, 1984); nowadays, it is one of the most 
investigated topics in the epigenetic field. Current efforts are mainly based on next generation 
sequencing (NGS) technique coupled with immunoprecipitation (ChIP-seq) (Barski et al., 
2007; Kouzarides, 2007)(for review see (Bell et al., 2011; Zhou et al., 2011)) in order to 
unequivocally define by a combinations of histone variants DNA sequences in their cellular 
roles. For example, the a.m. H3K4me1 is a signature for enhancers, or H3K4me3 
(trimethylated lysine 4 of histone 3) for promoters, H3K36me3 (trimethylated lysine 36 of 
histone 3) covers the 3’ end of genes, H3K27me3 correlates with gene repression, methylation 
of H3K9 has been implicated in heterochromatin formation, whereas its acetylation remarks 
active transcription, or the dynamic histone combination within a gene body guide the 
elongation of RNAPII (Heintzman et al., 2009; Barski et al., 2007; Boyer et al., 2006; 
Brookes and Pombo, 2009). Histone modifications represent therefore an important layer of 
transcriptional regulation. 
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1.2.4 Nucleosome positioning and remodeling 
The nucleosome structure is ubiquitous, though histone post-translational modifications and 
nucleosome positioning affect the chromatin structure, contributing to cell type specific gene 
regulation. Nucleosome positioning can affect gene regulation by masking (or protecting, for 
example preventing methylation on CpG) or exposing DNA sequences, thus allowing 
transcription factors or transcriptional complexes to bind. It has been shown that an actively 
transcribed gene displays a well-positioned nucleosome pattern around the first exon and a 
nucleosome free region just upstream the TSS (Schones et al., 2008),. Interestingly Andersson 
and colleagues could observe that nucleosomes tend to localize more often with internal exons 
than with intronic region (Andersson et al., 2009), supporting the emerging concept that 
splicing, transcription and chromatin depend on each other (Neugebauer, 2002). On this 
conceptual line, there are more and more evidences of an additional layer of regulation 
represented by intergenic transcript (Ebralidze et al., 2008; Kim et al., 2007; Orom et al., 
2010; Whitehouse and Tsukiyama, 2009). 
1.2.5 High-order structure 
The major chromatin unit in eukaryotes is the chromosome. Eukaryotic genomes are not 
randomly organized into the nuclei, but they occupy precise chromosomal territories (CT) 
(Cremer et al., 1982; Cremer et al., 2006; Hochstrasser et al., 1986; Misteli, 2008). A CT is 
the unit to measure the nuclear position occupied by a certain chromosome; the distribution of 
which can be described as radial position (Croft et al., 1999). This concept is very important 
because it allows quantification of the varying distribution across different cell type. Usually, 
CT correlates with the state of expression, where actively transcribed gene or cluster of genes 
are located in the interior and silenced regions are often observed in the periphery (Takizawa 
et al., 2008). However, CTs do not have rigid or physical boundaries, thus they are very 
flexible. The emerging idea is that clustering of genes in transcriptional hotspots contributes 
to their efficient and coordinated expression, like the HOX gene or T cytokines cluster (Cai 
and Kohwi-Shigematsu, 1999; Soshnikova and Duboule, 2009; Bergman et al., 2003) and to 
trans-interaction. This occurs not only for chromosomal translocation (Meaburn et al., 2007; 
Okuno et al., 2001) or different replication timing process, but also interchromosomal 
reversible interaction, which are important for gene regulation (Ling et al., 2006). 
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Figure 2: Different layers of epigenetic mechanisms involved in the chromatin organization. Chromatin 
organization in higher eukaryotes is achieved at different step, from modification in the primary sequences (here 
is depicted the example of cytosine methylation), to the nucleosomes levels, which controls the DNA 
accessibility. Histone tails post-translational modifications represent an ulterior layer, and they comprise active 
and repressive marks, few of which are indicated and discussed in the main text. Formation of heterochromatin is 
the next higher order structure, compacting chromosome regions which must be silenced. The last level of 
organization is the spatial organization of the chromosomes in the nuclear space. On the left part of the scheme 
repressive epigenetic mechanisms are depicted, contrasting the active ones (Zhou et al., 2011). 
 
In order to establish and maintain the nuclear architecture in a specific cell type context, 
chromatin organizer proteins have been identified during the last decades. In the last two 
paragraph of this chapter, two very important architects will be discussed, since they are 
involved in this thesis. 
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1.2.5.1 SatB1: architect in T cells 
SatB1 (special AT-rich binding protein 1) was originally identified in a complex with matrix 
attachment DNA regions (MARs) (Dickinson et al., 1992). MAR sequences were postulated 
to modify high order chromatin structure by mediating attachment of chromatin to 
topologically independent loop domains (Gasser and Laemmli, 1986). An example of the 
essential role of SatB1 mediated by MAR sequences is the binding of the L2a silencer, which 
regulates CD8a gene, encoding for an important cofactor of the T cell receptor (Banan et al., 
1997); another example is the transcriptional regulation of the immunoglobulin μ heavy chain 
for BCR (B cell receptor) (Forrester et al., 2004; Goebel et al., 2002). Here the high order 
chromatin structure affects transcriptional activity by promoting epigenetic changes, which 
turn the locus in an active status. This results in generation of specific domains accessible for 
binding of transcription factors, and extensive demethylation across the chromatin domain 
(Forrester et al., 2004; Regha et al., 2007; Villa et al., 2007).   
SatB1 is predominantly expressed in T cells. SatB1 knockout mice die after 3-4 weeks. These 
mice are thinner and smaller in size compared to the wild type littermate, but the only 
observed phenotype involves T and B cells. In fact, thymus and spleen are drastically smaller. 
Concentrating on the T cell phenotype (since in this thesis B cells will not be studied) in the 
thymus there are less immature progenitors but more double positive cells 
(CD4,CD8+)compared to the wt, indicating that SatB1 is determinant for T cell specification 
and development at multiple stages. Moreover, T cell activation in the periphery is impaired 
(Forrester et al., 2004; Alvarez et al., 2000).  
SatB1 ablation leads to gene dysregulation affecting hundred of genes (at least 2% of total 
gene) (Yasui et al., 2002). This global control on gene regulation can be achieved by the 
chromatin architecture established by SatB1: it has a unique cage-like distribution in 
thymocytes nuclei, establishing a unique intranuclear architecture by anchoring DNA 
sequences and exposing specific gene loci to tissue specific activation or repression by gene 
regulators as trans-acting transcription factor (SatB1 favors or inhibits their binding by the 
means of DNA accessibility) or cis acting mechanisms (as histone tail modifications). In other 
words, this unique structure differentiates between euchromatin and heterochromatin (Cai et 
al., 2003; Notani et al., 2010). With a such spatial organization SatB1 compacts the cluster of 
cytokine genes in loop-dense structure, allowing their coordinated transcription during T cell 
specification and differentiation (Cai et al., 2006; Galande et al., 2001). 
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All these studies point to a essential role of SatB1 in spatial organization especially in T cells, 
which contributes to regulate the multistep development of T cell at transcriptional level. 
1.2.5.2 CTCF: master weaver of the genome 
CTCF (CCCTC-binding factor) is the most widely studied insulator-binding protein in 
vertebrate. CTCF was originally discovered as a transcriptional inhibitor of chicken myc and 
lysozyme genes (Baniahmad et al., 1990; Lobanenkov et al., 1990). CTCF protein contains 11 
zing fingers, by which can mediate multiple DNA interaction. The same structure is 
maintained across vertebrates, being conserved from human to Drosophila (Moon et al., 
2005). Mapping CTCF binding site (BS) at genome wide level by deep sequencing ChIP 
technology had shown that many of them remain invariant across different human cell types 
(> 13.000; (Kim et al., 2007)), and are conserved among human, mouse and chicken CTCF 
BS (>200 BS are syntenic, meaning located in equivalent genomic position regardless of the 
sequence conservation; (Martin et al., 2011)). This suggests a crucial role of CTCF genome 
wide transcriptional regulation. 
It is an accepted paradigm that CTCF exerts its functions via establishing long-range 
chromatin interaction (Ling et al., 2006; Splinter et al., 2006). For this reason CTCF has been 
called ‘a master weaver of the genome’ (Phillips and Corces, 2009). CTCF’s functions can be 
summarized in four categories: it acts as 1) a barrier insulator by blocking heterochromatin 
spreading into active loci 2) an enhancer blocker 3) a three dimensional genomic organizer 4) 
a transcriptional enhancer. CTCF was found to block the spreading of repressive telomeric 
heterochromatin in S. Cerevisiae (Bell et al., 1999; Defossez and Gilson, 2002; Bowers et al., 
2009). By binding an insulator region CTCF coordinates  transcriptional activity of two 
genes, IL-3 (interleukin-3) and GM-CSF (Granulocytic-Macrophage Colony-Stimulating 
Factor), located in the same locus, but differently expressed within hematopoietic cell types. 
Multiple DNA methylation sensitive CTCF BS are located in the Xci (X chromosome 
Inactivation Center), suggesting a direct role of CTCF in X chromosome inactivation (Chao et 
al., 2002; Donohoe et al., 2009; Navarro et al., 2006). The imprinted locus Igf2 (Insulin-llike 
Growth Factor-2)/H19 had been studied in molecular detail: these two genes share an 
enhancer, whose activity induces H19 expression in maternal allele and Igf2 in the paternal 
one. This regulation is achieved by DNA-methylation sensitive CTCF binding to an enhancer 
blocking insulator located between the two genes (ICR=Imprinted Control Region). In the 
maternal allele CTCF binds to non-methylated ICR and blocks the enhancer function on the 
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Igf2 gene and vice versa in the paternal allele (Bell et al., 2001; Murrell et al., 2004; Fedoriw 
et al., 2004). 
Multiple evidences suggest a major role for CTCF as gene regulator by long-range 
interactions, both as repressor (Lutz et al., 2000) or activator (Hadjur et al., 2009). Few 
examples of the importance of CTCF in coordinating transcriptional regulation are the 
following: CTCF protects p53 gene in humans by maintaining the locus in an open state and 
avoiding its repression by incorporation of repressive histone marks in tumor cells (Soto-
Reyes and Recillas-Targa, 2010). CTCF plays a functional role in lymphoid pathway, both in 
T cell and B cell development: during T cell maturation, CTCF regulates cell cycle 
progression of specific subset of thymocytes (Heath et al., 2008). During B lymphoopoiesis, it 
is involved in the spatial organization of the Igh locus for a correct BCR rearrangement 
(Degner et al., 2011). CTCF binds also in the first intron of the key hematopoietic regulator 
Myb, forming an Active Chromatin Hub (ACH) which undergoes destabilization and 
consequent disruption during erythroid differentiation (Stadhouders et al., 2012). Moreover, 
CTCF-mediated loops in the ß-globin gene determine the chromatin conformation of the locus 
directly involving active and repressive chromatin mark throughout erythroid differentiation 
(Tolhuis et al., 2002; Splinter et al., 2006; Palstra et al., 2003; Dekker et al., 2002).  
CTCF is a crucial organizer of the high-order structure of chromatin, but plays also essential 
roles at local structure. These studies point to an emerging concept of epigenetic landscape, 
that controls and modulates trans-acting factors (as transcription factors) activity on gene 
transcription.  
1.3 Hematopoiesis 
Hematopoiesis is a developmental process of blood cells of all lineages.  The main cellular 
components of blood are erythrocytes, platelets and leukocytes (white blood cells). 
Erythrocytes transport oxygen from the lungs to all tissues through the circulation stream, 
platelets are responsible for blood coagulation and leukocytes, which are represented by  
myeloid and lymphoid cells, protect individuals from infection forming the immune system. 
Myeloid cells are monocytes, the precursors of tissue macrophage, and granulocytes; 
lymphoid cells are mainly T cells and B cells, and a small percentage of natural killer cells 
(Kawamoto et al., 2010). 
Apart from some rare so called memory lymphoid cells, all mature blood cells have a short 
lifespan ranging from hours for granulocytes to couple of months for erythrocytes. The 
15 
1 Introduction 
turnover of this system is constant throughout life, in man amounting to millions of cells per 
second in a steady state. This rate can rapidly increase even ten fold when challenged, e.g. by 
infection or bleeding, in order to compensate stress and maintain the system homeostasis 
(Ogawa, 1993; Kaushansky, 2006). To sustain this rapid turnover some progenitor cells exist 
in blood system. Such cells are Hematopoietic Stem Cells (HSC) (Adolfsson et al., 2005; 
Wilson and Trumpp, 2006) which differ from the more differentiated counterparts in 
possessing a combination of two properties: they can generate more HSCs (a process called 
self-renew) and are pluripotent, meaning they have the potential to stepwise differentiate into 
all mature blood cells (Orkin, 2000). In adult hematopoiesis (after birth), HSCs reside in the 
bone marrow in specialized cellular structures, essential for maintenance of adult HSCs 
(Wilson et al., 2009). All blood cells are generated in bone marrow, except T cell lineage, 
which develops in the thymus from progenitors derived from these organ (Weissman et al., 
2001; Rothenberg et al., 2008).  
Hematopoiesis is usually depicted in a hierachical fashion, starting from HSC differentiation 
first to progenitors and then to precursors with varying commitments to multiple or single 
pathway (Orkin, 2000). Differentiation is defined as a sequence of events through which 
immature precursor becomes mature effector cells. During differentiation stem cells give rise 
to progeny that progressively lose self-renewal capacity and become restricted to specific 
lineage (Akashi et al., 2000); this lineage restriction is also referred to as “cell fate decision” 
or “lineage commitment”. In the last decades several models have been proposed to describe a 
hierarchy of the hematopoietic system (Kondo et al., 1997; Reya et al., 2001), and a 
simplified version of the hierarchy which aim to merge different proposed models (Adolfsson 
et al., 2005; Kawamoto et al., 2010; Wilson and Trumpp, 2006) is depicted in Figure 1. 
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Figure 3: schematic view of the hierarchy of hematopoietic populations. All hematopoietic cells derive 
from the HSCs, which differentiate into an intermediate MPP (multipotent progenitor) stage, which again can 
differentiate in all lineages but lost the stem cell property of long-term self-renewal. The model postulates that 
the binary decision between myeloid and lymphoid pathway occurs at this level. However, as underlined from 
severale cross-lineage arrows, based on transdifferentiation assays, the illustrated hierarchy is an hypothetic 
flexible system. Lymphoid and myeloid progenitors (CMP-GMP and CLP) are at this point primed for a specific 
lineage commitment, which will end up in effector cells through stepwise maturation processes (Cedar and 
Bergman, 2011). 
 
The hematopoietic system is intensively studied for regulation of cell fate decision, since it 
provides a valuable model for examining genetic programs, established and executed in 
vertebrates, and alteration of blood homeostasis in pathological processes, as leukemia. First 
of all, it is relatively easy to isolate hematopoietic cells from mice. Hematopoietic cells are 
found in several organs of the body: the bone marrow (BM) contains adult HSCs, 
myeloerythroid and B-lymphoid progenitors and consists largely of mature blood cells. In the 
spleen and lymph nodes are found the majority of mature B and T cells, but also macrophages 
and granulocytes. The thymus is mostly populated by T cells carrying the T cell receptor 
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(TCR) and still expressing both CD4 and CD8 (double positive, DP cells) and in a little extent 
by T cell progenitors. Mature hematopoietic cells are also present in the peritoneum and in the 
peripheral blood. Secondly, many hematopoietic populations with different lineage 
capabilities and at various stage of differentiation were defined by isolation though the using 
monoclonal antibodies that recognize specific surface markers (CD = cell determinants). 
Therefore, it is possible to stain isolated tissue with different combination of antibodies and 
characterize distinct hematopoietic cell lineages by FACS (Fluorescence Activated Cell 
Sorting) at a single cell level. By this technique is not only possible to analyze a distribution 
of different lineages in a tissue, but also to sort specific populations for further functional 
assays (Forsberg et al., 2006). 
1.3.1 Transcription factors regulate hematopoietic development 
In hematopoietic development, blood cells acquire defined phenotypes as a result of 
coordinated regulation of cell-specific molecular pathways, involving cytokines receptors and 
transcription factors (Kondo et al., 2000; Shivdasani and Orkin, 1996; Zhu and Emerson, 
2002). It is clear that transcriptional factors play a key role in the determination of cell fate 
programs by promoting or repressing lineage-specific genes. However, there is no single 
“master” transcription factor, which is responsible for pivotal steps of differentiation; rather, 
gene expression is controlled by combinatorial function of several transcription factors, 
resulting in cell type specific network (Rosenbauer and Tenen, 2007; Rosmarin et al., 2005). 
To define these networks of lineage-specific expression profiles on a large scale, genome 
wide technologies as microarrays and next generation deep-sequencing analysis are carried 
out on different blood cells populations in the last decade (Forsberg et al., 2006). A bottom-up 
approach investigating a role of specific transcription factors, especially in very rare 
haematopoietic populations (difficult to be purifying and studied), consists in genetic 
strategies, primarily gene-targeting (knock-out, knock-in and transgenic approach) and 
consequent gene overexpression or downregulation using retroviral vectors (Zhu and 
Emerson, 2002; Laiosa et al., 2006). Mouse models lacking a specific transcription factor do 
not only play an important role in understanding major changes in the haematopoietic 
development, but provide a reproducible biological material to perform genome-wide analysis 
on different cell populations. Up to now, the role of distinct hematopoietic transcription 
factors in lineage commitment and cell fate decision has been widely investigated in last 
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decades, predominantly by a loss or gain-of- function mouse models: However, there are still 
many aspects, which remain elusive (Bonadies et al., 2011). 
1.3.2 Leukemia: when hematopoiesis is perturbed 
The hematopoietic system has been studied in detail in order to understand the etiology of 
leukemia from macroscopic changes up to molecular details. Leukemia refers in general to all 
blood cancers, including myeloma, myeloid leukemia and myelodysplastic syndromes. The 
word ‘leukemia’ derives from ancient Greek: λευκό/lephko means white and αίμα/hema is the 
suffix pertaining to blood: leukemia is in fact a malignant disease marked by altered 
proliferation and development of leukocytes and/or their precursors in blood-forming organs, 
affecting bone marrow, blood cells, lymph nodes and other part of the lymphatic system. 
Since this thesis investigates acute myeloid leukemia (AML), this chapter will focus only on 
this particular type of leukemia.  
AML is a predominant type of acute leukemia in adults. The median age at diagnosis is 67 
years (Estey, 2012a). Leukemia, mainly AML and T-ALL (T cells acute lymphoblastic 
leukemia) are together the main cause of death by cancer in childhood (Deneberg, 2012).. 
AML is characterized by an accumulation of granulocytic or monocytic precursor in the bone 
marrow. It is a very heterogeneous cancer, therefore complicated to classify. The most widely 
used classification is still the French American British scheme (FAB), which was first 
proposed in 1976. It relies on morphologic, cytochemical, and immunophenotypic features of 
the neoplastic cells to establish their lineage and degree of maturation, taking into account 
genetic lesions. Following these criteria, AML can be divided in 7 subtypes, named M0-M7 
according with increasing degree of differentiation of the cancer blasts. Incidence and 
prognosis are also approximately indicated in the table below.  
Current treatment options include chemotherapy, allogenic stem cell transplantation of bone 
marrow, and other drug therapies. Current efforts are directed to identify novel genetic and 
epigenetic markers or combination of them in order to design specific drugs for specific AML 
(see for review, (Estey, 2012b)). 
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FAB 
subtype 
Name % of adult 
AML patients 
Prognosis compared 
to average for AML 
M0 Undifferentiated acute myeloblastic 
leukemia 
5% worse 
M1 Acute myeloblastic leukemia with 
minimal maturation 
15% average 
M2 Acute myeloblastic leukemia with 25% better 
M3 Acute promyelocytic leukemia (APL) 10% best 
M4 Acute myelomonocytic leukemia 20% average 
M4 eos Acute myelomonocytic leukemia with 
eosinophilia 
5% better 
M5 Acute monocytic leukemia 10% average 
M6 Acute erythroid leukemia 5% worse 
M7 Acute megakaryoblastic leukemia 5% worse 
Table 1: French-American-British (FAB) classification. Incidence frequency and prognosis predictions 
are also indicated (Jemal et al., 2002). 
 
The role of genes involved in leukemogenesis has not been yet completely understood, 
leaving open questions on gene regulation and pivotal transcription factors. Ideally, such a 
molecular approach has to be integrated with clinical research in a translational medicine 
perspective. So far investigations of AML pathogenesis mainly focus on the expression 
analysis of oncogenes (Mueller and Pabst, 2010; Pabst and Mueller, 2007) and tumor 
suppressor genes  that regulate cell proliferation and differentiation.This thesis focuses on 
master transcription factor PU.1 and investigates its role in regulation of hematopoiesis and 
involvement in leukemogenesis. 
1.4 Master hematopoietic transcription factor PU.1 
PU.1, a widely studied member of the large family of Ets transcription factors, plays a crucial 
role in all hematopoietic cell types, since it is a primary lineage determinant from the early 
progenitor state. PU.1 is required for myeloid and lymphoid lineages development for 
orchestrating a transcriptional network specific for each of the lineages. PU.1 is expressed in a 
lineage specific manner throughout the hematopoietic system; it can be detected at low levels 
in HSCs and in LMPP, low and constant levels during B-cell development, is upregulated in 
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the myeloid compartment, and becomes absent in the erythroid and in T-cell lineages(Scott et 
al., 1994; Klemsz et al., 1990; Iwasaki et al., 2005). 
The Pu.1 gene consists of 5 exons and is located on chromosome 2 (2.E3) in mouse and 11 
(p11.22) in human. The homology between the proteins is 85% (264 amino acids of the 
human and 266 or 272 amino acids of the murine one, depending on the initial transcription 
codon); the DNA exon sequences are evolutionary conserved between the two species by 
meaning of more than 75% (Gupta et al., 2009). The PU.1 protein consists of four different 
domains: 1) the ETS domain at the carboxyl terminus, which mediates both protein 
interactions (with partner such as C/EBP, c-Jun, GATA-1 and Runx1) as well as binding to 
the DNA by a loop-helix-loop structure, 2) the PEST domain which is essential for protein-
protein interactions (such as IRFs family members) 3) a glutamine-rich domain, which 
interact with GATA-1, GATA-2 and RB (retinoblastoma protein) and 4) an acidic domain, 
which can recruit components of the basal transcriptional machinery (such as TFIID and 
TBP); therefore the last two domains are together considered as trans-activating domain for 
the direct role of recruiting essential factor of the transcriptional machinery for the initiation 
of transcription and the recruitment of RNA polymerase II.  
 
 
Figure 4: schematic representation of the PU.1 protein and relative domains. Several proteins, mostly 
transcription factors, interact with PU.1 promtoer. The ETS domain is the best conserved within the ETS-
transcription factors. 
The interaction with protein partners may result in positive (c-Jun) or negative (GATA-1), or 
synergic (C/EBPα) effects on PU.1 function: the stechiometric balance between PU.1 and 
GATA-1 determines myeloid (higher PU.1 expression) against megakaryocyte-erythroid cell 
fate (higher GATA-1 expression) by reciprocal displacement at DNA binding site of target 
genes (Chou et al., 2009; Nerlov et al., 2000; Rekhtman et al., 1999; Stopka et al., 2005). c-
Jun interacts with PU.1 promoting myeloid transcriptional program, and associated binding to 
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the DNA of C/EBPα and PU.1 marks specificly monocyte target gene after myeloid 
commitment (Dahl et al., 2003; Heinz et al., 2010; Laslo et al., 2006; Behre et al., 1999; 
Grondin et al., 2007).  
The PU.1 binding site recognized by the EST domain consists of a purine-rich sequence core 
(5’GGAA), which is present in the promoter region or in distal sequence of its target genes. 
Through the trans-activation DNA domain PU.1 can bind upstream the promoter, interact 
with the TATA binding protein and universal cofactors like Sp1 or hematopoietic cofactors 
like AML-1, inducing the initiation of transcription. Most of PU.1 targets are the key factors 
for myeloid and lymphoid differentiation like receptors for lineage specific cytokines. Some 
examples are macrophage, granulocyte or both colony stimulating factor receptor (M-CSFR; 
G-CSFR; GM-CSFR) for the myeloid lineage, or IL7Rα, immunoglobulin (Ig) light- (κ and 
λ) and heavy- (µ) chain gene, required for a correct B cell development (Friedman, 2007).  
Since different levels of PU.1 modulate blood cell fate decision and deregulation of PU.1 
leads to abnormal hematopoiesis and might be involved in leukemogenesis, it is important to 
understand how Pu.1 gene is regulated in distinct population types. 
1.4.1 PU.1 role in hematopoiesis by in vivo mouse models 
PU.1 has emerged as a central regulator of hematopoiesis and elicits its function in an 
orchestrated and coordinated manner with lineage specific transcription factors networks. For 
this reason it is important to investigate its role using in vivo models, which allows studying 
the consequence of the PU.1 loss or overexpression in the whole hematopoietic system. 
Several mouse models have been developed in the past 20 years and some of them as listed in 
the table below (Table 2). Since PU.1 knockout is embryonic or neonatal lethal, conditional 
strains were generated, to understand the consequence of PU.1 loss of function in a specific 
lineage. Another approach involves gene regulation studies, with consequent ablation of 
regulatory elements or indispensable genomic region for PU.1 gene transcription. These 
models aim to perturb PU.1 expression pattern and observe the phenotype resulting from 
lower than physiological (Houston et al., 2007; Rosenbauer et al., 2004) or higher (Anderson 
et al., 2002; Moreau-Gachelin et al., 1996) PU.1 levels. 
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Type of 
mutation 
Genetic modification Main phenotype Reference 
Overexpression PU.1 transgene driven by LTR 
from SFFV virus 
Erythroleukemia Moreau-Gachelin et 
al. (1996) 
Null allele Inserion of neomycin cassette into 
exon 5, disrupting the Ets domain 
Late fetal / neonatal death. 
No fetal B,T, and myeloid cells 
Scott et al. (1994) 
McKercher et al. 
(1996) 
B cell specific 
deletion 
Deletion of floxed exon 5 with 
CD19-cre 
Development of functional B 
cells 
Polli et al. (2005) 
T cell specific 
deletion 
Deletion of floxed exon 5 with 
Lck-cre 
Impaired response for allergic 
inflammation (TH9 phenotype) 
Chang et al. (2010) 
Inducible 
deletion 
Poly-IC induced deletion of floxed 
exon 5 with Mx1-cre in aduts 
Granulocytic expansion and 
myeloid leukemia 
Dakic et al. (2005) 
Metcalf et al. (2006) 
Deletion of -
14Kb URE 
PU.1 kd/kd Block in T cell differentiation, T 
cell lymphoma in 70% of mice. 
Block of B cell differentiation in 
BM and expansion of B1 cells. 
Late development of myeloid 
leukemia (AML) 
Rosenbauer et al. 
(2006) 
Table 2: List of the main mouse models generated to study PU.1 role in hematopoiesis. Several models 
have been developed, and here only a summary of those is given, focusing on the main phenotype as 
representative example of the investigated lineages. 
 
Summarizing the outcome of these models, it has been proved that PU.1 is necessary for 
myeloid pathway development, commitment and differentiation, although its high levels in 
mature macrophages are maintained by default; PU.1 is dispensable for B lymphopoiesis but 
not for lymphoid commitment (Polli et al., 2005). PU.1 must be downregulated during T cell 
development and for erythroid lineage (Rothenberg et al., 1999; Moreau-Gachelin et al., 
1988; Rao et al., 1997); even if expressed at lower level, PU.1 plays a role in periphery 
activation of TH9 lineage, involved in allergic inflammation, by regulating interleukin-9 
production (Chang et al., 2010). Importantly, PU.1 perturbation is sufficient to lead to 
leukemic transformation in vivo, enlightening its role as tumor suppressor (Rosenbauer et al., 
2006). 
After summarizing PU.1 role in hematopoietic development in vivo, in the next chapter PU.1 
gene regulation will be discussed. 
1.4.2 PU.1 gene regulation 
In vivo mouse models represent a powerful approach to investigate the role of a gene in 
physiological onset, as well as loss and gain of function effects in different lineages. 
However, mouse models actively perturbing PU.1 expression are not useful for understanding 
the molecular mechanisms involved in establishing PU.1 transcriptional activity. To address 
this question, multiple studies have been performed to figure out how PU.1 gene is regulated. 
PU.1 gene doesn’t contain the standard TATA box, and PU.1 promoter is not sufficient to 
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drive alone luciferase expression in reporter assay (Li et al., 2001). Instead, PU.1 gene 
regulation is orchestrated by multiple regulatory elements not in the promoter region, 
responsible for its graded and lineage-specific expression: it has been shown, there is a cluster 
of discrete regulatory regions upstream the PU.1 promoter, with different dynamics 
throughout hematopoietic cell types (Leddin et al., 2011; Zarnegar et al., 2010). Among these, 
the URE (upstream regulatory element: located -14Kb or -17Kb upstream the PU.1 promoter, 
in mouse and human, respectively) has been widely investigated because of its primary role in 
PU.1 gene regulation. The URE function is necessary for PU.1 expression already in the stem 
cell compartment (Steidl et al., 2006). Different studies support the hypothesis that the URE is 
crucial for opening the PU.1 locus and therefore stepwise conditioning its expression at 
progenitors level, both myeloid or in lymphoid pathway. Several pivotal transcription factors 
have been found to bind the URE region: RUNX1, a master hematopoietic transcription factor 
essential for lineage commitment in the stem cell compartment and throughout hematopoietic 
development (Hoogenkamp et al., 2009; Huang et al., 2008), Ikaros, priming stem cell for 
lymphoid commitment (Zarnegar and Rothenberg, 2012), SatB1, a chromatin organizer and 
major repressor during T cell development (Steidl et al., 2007), member of the LEF/TCF 
family, downstream target of Wnt signalling (Rosenbauer et al., 2006), Egr family members, 
involved in establishing myeloid transcriptional network together with PU.1 (Hoogenkamp et 
al., 2007), NF-κB,  an activator of PU.1 transcription (Bonadies et al., 2010) and PU.1 itself, 
via an autoregulation transcriptional loop (Okuno et al., 2005). 
Besides the URE, another element (-12Kb upstream the PU.1 promoter) has been identified as 
an enhancer in myeloid cells but not in B cells, suggesting that the threshold of PU.1 
expression maintained by an additional autoregulatory loop can discriminate between high 
and intermediate PU.1 expression (Leddin et al., 2011).  
Rothenberg and Zarnegar (Zarnegar et al., 2010) dissected the whole cluster of conserved 
region after identification of two different additional elements in a proximity to the URE 
region. Function analysis of the elements was performed in vitro, by comparing myeloid cell 
with immature T cell lines, and Runx1 dosage-dependent PU.1 regulation model was 
proposed, where levels of Runx1 establish its binding through mutliple discrete elements in a 
cell-type specific manner, favoring myeloid factors to enhance PU.1 transcription or 
cooperating with T cell specific factors as Ikaros strongly silence PU.1 locus. The two models 
below represent current hypothesis of PU.1 gene regulation. It appears clear though, that 
many components and their interactions should be investigated in detail. 
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Figure 5: Most recent models for PU.1 gene regulation. Several studies investigate PU.1 gene regulation. 
Depending on the approach, there are several proposed models, but all of them have some shadowed aspects 
which remain unknown. For instance, the model of Rothenberg and colleagues (on the left) (Zarnegar et al., 
2010) is based only on in vitro gel shift assay modulating Runx1 levels; for that reason, a lot of complexes could 
not been identified, in fact there are named as “myeloid factor” or “T-cell factor”. However, this model provided 
the first evidence of the existence of a cluster of discrete elements, in addition to the previously described URE. 
The model on the right was proposed by a previous work of our lab (Leddin et al., 2011): here the focus is 
directed on the differential activation state of the PU.1 gene from an intermediate state (B-.cells) toward a very 
active state (macrophages), explained by the function of a novel enhancer.  
1.4.3 PU.1 as tumor suppressor: lessons from AML 
Given the importance of PU.1 for normal hematopoiesis, PU.1 represents an obvious target 
for disruption in AML. Indeed, mutations of the PU.1 gene were detected in 7% of patients 
with AML. The mutations decreased PU.1 ability to interact with the other partner protein, 
such as RUNX1 or c-Jun, therefore diminishing their synergistic effect on transcriptional 
regulation of target genes, responsible for myeloid differentiation (Mueller et al., 2003). 
However, these point mutations are too rare to explain the high frequency of PU.1 
dysregulation in AML patients (Mueller et al., 2003; Mueller et al., 2006b; Zhu et al., 2012). 
In fact, PU.1 expression and function are often altered by other mechanisms. PU.1 is known 
to be a target of three fusion products, frequently generated in leukemias due to chromosomal 
translocations.. AML1-ETO, a fusion product generated by (8;21) translocation, is found in 
10% of AML. This oncogene can ablate the function of RUNX1 (AML1), leading to 
leukemia. PU.1 function is down-regulaed by AML1-ETO through protein-protein 
interactions and consequent displacing of the PU.1 transcriptional coactivator (Vangala et al., 
2003), c-Jun. FLT3-ITD (tyrosine receptor kinase FLT-3 with internal tandem duplications, 
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which lead to constitutive activation) mutation occurs in 25% of AML. This oncogene 
represses PU.1 transcription (Mizuki et al., 2003). PML-RARα, resulting from the (15;17) 
translocation, is the genetic hallmark of APL M3 leukemia (98% cases). As FLT3-ITD, also 
PML-RARα, inhibits PU.1 at transcriptional level (Cook et al., 2004; Grignani et al., 1998; 
Mueller and Pabst, 2006; Walter et al., 2005). Importantly, treating APL with ATRA (all-
trans retinoic acid), which neutralize the function of the fusion oncogene, results in PU.1 
upregulation and differentiation of leukemic blasts (Huang et al., 2008). 
Inactivation of PU.1 in adult mice is sufficient for leukemia development. And URE knockout 
mice, where PU.1 expression is downregulated up to 20%, develop AML. Additionally, Steidl 
and colleagues (Steidl et al., 2007) identified a SNP (single nucleotide polymorphism) within 
the URE region, which is associated more frequently with complex karyotype leukemia (pour 
prognosis). 
1.5 Aim of the thesis 
Transcription factor PU.1 plays a major role in hematopoietic development as lineage priming 
determinant. PU.1 is expressed in a dynamic pattern in different lineages and alteration of 
PU.1 levels can lead often to leukemia or proliferative disorders. It is therefore necessary to 
understand the molecular mechanisms behind PU.1 cell-type specific gene regulation. In the 
last decades PU.1 gene regulation has been widely investigated in the myeloid and B-cell 
compartment. However, little is known about PU.1 regulation in T-cells. PU.1 must be in fact 
actively silenced during T cell lymphopoiesis, and lack of its downregulation leads to T-cell 
leukemia.  
On the other hand, high levels of PU.1 are required for myeloid differentiation, and PU.1 
expression block at early myeloid progenitors has been observed in human acute myeloid 
leukemia.  
Thus, this thesis aims to understand how PU.1 is downregulated in T-cells and blocked in 
acute myeloid leukemia by investigating the 3 dimensional chromatin structure of the PU.1 
locus.  
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2 Materials and Methods 
2.1 Materials 
2.1.1 General equipment 
Mastercycler Gradient        Eppendorf 
7300 Real Time PCR System       Applied Biosystems 
Multicentrifuge 3 S-R        Heraeus 
Geldoc 2000         Biorad 
Thermomixer         Eppendorf 
Agarose gel chambers        Biosteps 
Power supply EV231        Consort 
Flow hood          BDK 
Microscope DMIL         Leica 
Nanodrop          PeqLab 
FACS LSRII          BD 
Incubator          Binder 
Luminometer         Berthold Technologies 
Stratalinker 2400         Stratagene 
PDVF membrabe         Pall Corporation 
XAR film          Kodak 
Hypercassette         Amersham 
Phosphoimager cassette FLA-3000      FUJI 
Fuji RGII photographic system       FUJI 
7300 Real Time PCR System      Applied Biosystem 
CFX96 Real Time System       Biorad 
2.1.2 Cell culture equipment 
Cell culture dishes and flasks, sterile      TPP or Falcon 
Centrifuge tubes, sterile, different sizes      TPP or Falcon 
Serological pipettes         Falcon 
Neubauer cell-counter chamber       Superior Marienfeld 
Needles for single-use, sterile, different sizes     Neoject 
Polystyrene tubes, 5mL        BD Falcon 
Cryotubes, sterile, 1.5mL        Nunc 
Cell strainer, sterile, different sizes      BD 
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2.1.3 Mouse dissection equipment 
Dissecting board and pins 
Forcipes and scissors of different sizes     Brand 
Scalpels, sterile        Cutfix 
2.1.4 Chemicals and reagents 
1Kb ladder          Fermentas 
100bp ladder          Fermentas 
Agarose          Roth 
Ammonium persulfate (APS)       Roth 
ATP           Roth 
[α-32P]dCTP         Amersham 
Bromophenol blue        Roth 
BSA           Roth 
CaCl2          Roth 
Chlorophorm/Isoamylalcohol       Roth 
dNTPs 10mM each         Fermentas 
DTT           Roth 
Ethanol absolute        MDC Lager 
Ethidium bromide         Roth 
Formaldehyde 37%         Roth 
Giemsa stain         Roth 
Glacial acetic acid         Roth 
Glycerol          Roth 
Glycine          Roth 
Glycogen          Roth 
HEPES          Roth 
Hybri-Quick          Roth 
Isopropanol          Roth 
KCl          Roth 
KH2PO4         Roth 
IPTG           Roth 
KCl           Roth 
LB medium          Roth 
LB agar          Roth 
LiCl           Roth 
Methanol          Roth 
MgCl2          Roth 
28 
2 Materials and Methods 
NaCl          Roth 
Powder milk          Roth 
NaCl           Roth 
NaHCO3         Roth 
NaOH          Roth 
Nonidet P-40         Sigma-Aldrich 
Pageruler prestained protein ladder      Fermentas 
Phenol          Roth 
Polyacrilammide 37.5:1        Roth 
Propidium iodide         Sigma-Aldrich 
Proteinase K (stock 10mg/mL)      Roth 
Proteinase inhibitor cocktail       Roche 
RNase free water        Fermentas 
Sodium citrate         Roth 
Sodium butyrate        Roth 
Sodium dodecyl sulphate        Roth 
TEMED          Roth 
Trichlormethan (Chloroform)      Roth 
Triton X-100          Roth 
Tris base          Roth 
Tris-HCl          Roth 
Xylene cyanol         Roth 
2.1.5 Buffers and solutions 
ACK (red blood cells lysis buffer)       0.15 M NH4Cl, 10 mM KHCO3,  
          0.1 mM EDTA, pH 7.3 in water 
 
ChIP cell lysis buffer       10 mM Tris pH 8.0, 10 mM NaCl,  
          0.2 % NP40, protease inhibitors 
 
ChIP nuclei lysis buffer^       50 mM Tris pH 8.1, 10 mM EDTA, 
          1 % SDS, protease inhibitors 
 
ChIP IP dilution buffer       20 mM Tris pH 8.1, 2 mM EDTA,  
          150 mM NaCl, 1 % Triton X-100,  
          0.01 % SDS, protease inhibitors 
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ChIP IP wash buffer 1       20 mM Tris pH 8.1, 2 mM EDTA,  
          50 mM NaCl, 1 % Triton X-100,  
          0.1 % SDS, protease inhibitors 
 
ChIP IP wash buffer 2 10 mM Tris pH 8.1, 1 mM EDTA, 0.25 M 
LiCl, 1 % NP40, 1 % deoxycholic acid, 
protease inhibitors 
 
ChIP elution buffer        100 mM NaHCO3, 1 % SDS 
 
Nuclear extract buffer A       10 mM HEPES pH 7.9, 1.5 mM MgCl2, 
          10 mM NaCl, protease inhibitors 
 
Nuclear extract buffer C       20 mM HEPES pH 7.9, 25 % glycerol,  
          0.42 M NaCl, 1.5 mM MgCl2,  
          0.2 mM EDTA 
 
FACS buffer          2 % (v/v) FCS, 2 mM EDTA, in PBS 
 
Freezing medium         50 % (v/v) medium, 40 % FCS (v/v), 
          10 % (v/v) DMSO 
 
Phosphate buffered saline (PBS)  137 mM NaCl, 2.7 mM KCl, 10 mM 
Na2HPO4, 2 mM KH2PO4, pH 7.4  
 
Southern blot wash solution I       100 ml 20 x SSC, 10 ml 20 % SDS, 
          in 890 ml water 
 
Southern blot wash solution II       10 ml 20 x SSC, 10 ml 20 % SDS,  
          in 980 ml water 
 
Tail digestion buffer  10 mM Tris-HCl pH 8.0, 10 mM EDTA 
pH 8.0, 50 mM NaCl, 0.5 % (v/v) SDS, 
 
TE buffer          10 mM Tris, 1 mM EDTA, pH 7.5  
 
3C cell lysis buffer        10 mM Tris pH 8.0, 10 mM NaCl,  
          0.2 % NP40, protease inhibitors 
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1x EMSA binding buffer       20 mM Hepes, pH 7.6, 10 % glycerol, 
         2 mM EDTA, 2 mM DTT, 10 mM 
MgCl2, 100 mM KCl in water 
 
1x SDS sample buffer       0.5 M Tris-HCl pH 6.8, 5 % glycerol,  
2 % SDS and 100 mM DTT  
 
1x TAE          40 mM Tris acetate, 2 mM EDTA, pH 8.5  
 
1x TBE          10.8 g Tris base, 5.5 g boric acid,  
0.93 g EDTA add 1000 ml water 
 
1x transfer buffer        3.4 g Tris-base, 14.4 g glycine,  
200 ml methanol, add 1000 ml water 
 
1x western running buffer       3.4 g Tris-base, 14.4 g glycine,  
          5 ml 20 % SDS, add 1000 ml water 
 
4x Tris/SDS pH 6.8 18.6 g Tris-base, 6 ml 20 % SDS, pH 6.8 
with HCl, add 300 ml water 
 
4x Tris/SDS pH 8.8 91 g Tris base, 10 ml 20 % SDS, pH 8.8 
with HCl, add 500 ml water 
 
6x Loading buffer for agarose gel electrophoresis    0.25 % (w/v) bromphenol blue,  
0.26 % xylene cyanol (w/v),  
30 % glycerol (v/v), in water  
 
20x SSC          3.0 M NaCl, 0.3 M sodium citrate, 
1 mM EDTA  
2.1.6 Cell culture media and reagents 
Dulbecco’s modified Eagle’s Medium (DMEM)    PAA 
RPMI 1640, with HEPES        PAA 
RPMI 1640 with HEPES, sodium carbonate, glucose    Gibco-Invitrogen 
Fetal Calf Serum (FCS)        Biochrom 
Penicillin/streptomycin, 100 x concentrate     PAA 
Stable glutamine, 200mM concentrate      PAA 
Trypsin EDTA (1:250), 1 x Concentrate      PAA 
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ß-mercaptoethanol 50mM        Gibco-Invitrogen 
N,N-dimethylsulfoxide (DMSO)       Roth 
Polybrene or Hexadimethrine bromide      Sigma-Aldrich 
G418 sulphate         Invitrogen 
Puromycin          Roth 
Doxocyclin         Sigma 
5-AZA-cytidine        Sigma 
2.1.7 Enzymes and appending buffers 
Restriction endonucleases 10.000-50.000 unit/mL    Fermentas 
10x red, green, blue, orange, tango, EcorI, BamHI, SacI  buffers  Fermentas 
ApoI 10.000 unit/mL and buffer 3       NEB 
BglII 50.000 unit/mL and buffer 3      NEB 
MspI and buffer 3         NEB  
Klenow fragment and 10x buffer       Fermentas 
Taq polymerase and 10x KCl buffer      Fermentas 
Pfx proof reading Taq polymerase and 10x buffer    Invitrogen 
GoTaq Taq polymerase and 5x buffer      Promega 
2x Mastermix SYBR Green       Applied Biosystems 
2x Mastermix TaqMan        Applied Biosystem 
T4 Ligase 500u/μL and 10x buffer       NEB 
T4 Ligase high concentrated 2000u/μL      NEB 
Retrotranscriptase         Fermentas 
DNase          Invitrogen 
RNase out          Fermentas 
RNase I          Fermentas 
X-Galatossidase         Roth 
2.1.8 Kits 
Invisorb Spin DNA extraction kit       Invitek 
Invisorb Spin Plasmid mini two       Invitek 
Purelink HiPure plasmid Maxiprep kit      Invitrogen 
Purelink HiPure plasmid Miniprep kit      Invitrogen 
MSB Spin Rapace kit        Invitek 
QIAquick Nncleotide Removal Kit      Qiagen 
ECL Western Blot         Invitrogen 
RNease Micro kit         Qiagen  
Calcium Phosphate Transfection kit      Invitrogen  
TurboFect Transfection Reagent       Fermentas 
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Amaxa Cell Line Nucleofector Kit L      Lonza 
Dual-Luciferase Reporter Assay System      Promega 
LowCell ChIP kit        Diagenode 
 
2.1.9 Antibodies 
ANTIBODY AGAINST   APPLICATION   SUPPLIER  
acetyl histone H3(H3K9Ac)  ChIP     Santa Cruz Biotechnology 
trimethyl histon H3 (H3K27me3)  ChIP     Santa Cruz Biotechnology 
SatB1       ChIP/western/EMSA  Santa Cruz Biotechnology 
SatB1       ChIP (mouse)    Kohwi-Shigematsu lab 
CTCF (human, mouse)   ChIP/western    Millipore/Upstate 
Rabbit IgG     ChIP/EMSA    Millipore/Upstate 
Goat IgG     ChIP/EMSA    Sigma 
ß-TUBULIN     western    Sigma 
ß-actin     western    Sigma 
anti-mouse IgG-HRP   western (II)    Santa Cruz Biotechnology 
anti-rabbit IgG-HRP    western (II)    Santa Cruz Biotechnology 
anti-goat IgG-HRP    western (II)    Santa Cruz Biotechnology 
2.1.10 Micro Beads and FACS antibodies 
mouse CD19 microbeads       Miltenyi 
mouse CD117 microbeads       Miltenyi 
human CD3 microbeads       Miltenyi 
human CD19 microbeads       Miltenyi 
human CD34 microbeads       Miltenyi 
mouse CD19-FITC        Miltenyi 
mouse CD117-APC        Miltenyi 
human CD3-FITC        Miltenyi 
human CD19-PE        Miltenyi 
human CD34-FITC        Miltenyi 
CD117-APC          BD 
CD11b / Mac1-APC        Biologend  
Sca1-PE          Biolegend 
2.1.11 Cell lines and mouse strains 
CELL / MOUSE        REF: / ATCC NR 
B6 wild type mice         Taconic 
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Transgenic human PU.1 PU.1-/- background     (Leddin et al., 2011) 
HEK-293T         CRL-11268 
HeLa          CCL-2 
PlatE          (Morita et al., 2000) 
EL-4          TIB-39 
416B           
Jurkat          TIB-152 
HL-60          CCL-240 
U937          CRL-1593.2 
Inducible Jurkat cells        (Ngo et al., 2006) 
2.1.12 Oligonucleotides  
Oligos were purchased by Metabion, MWG, Invitrogen or Biotez. Taqman probes were provided by ABI. 
In the following tables, m means oligo specific for mouse genome, h for human; F stays for forward and R for 
reverse. In the reference column is indicate the origin of the primers, either from a previous published work or 
from the internal database of the Rosenbauer research team (the OR nnumbers) 
 
GENOTYPING PCRs SEQUENCE 5’-3’ REFERENCE 
m PU.1 KO 1  ctt cac tgc cca ttc att ggc tca tca (Scott et al., 1994) 
m PU.1 KO 2 gct ggg gac aag gtt tga taa ggg aa (Scott et al., 1994) 
m PU.1 KO 3 caa ccg gat cta gac tcg agg a (Scott et al., 1994) 
h BAC PCR1 F ggc aat atg tca ggg agg tg (Leddin et al., 2011) 
h BAC PCR1 R atg act gga tgg gac tgg ag (Leddin et al., 2011) 
h BAC PCR2 F cat ctg atc ccc tcc aga ga (Leddin et al., 2011) 
h BAC PCR2 R cag caa agg ctt ttg aga cc (Leddin et al., 2011) 
GFP F ctg acc tac ggc gtg cag tg OR25 
GFP R gtt ctg ctg gta gtg gtc gg OR24 
PSK T7 F taa tac gac tca cta tag g  OR460 
PSK M13 rev cac aca gga aac agc tat gac ca OR461 
m/h PU.1 promoter F atc agg aac ttg tgc tgg ccc tgc OR41 
 
CLONING FOR 
LUCIFERASE 
SEQUENCE 5’-3’ REFERENCE 
m -25kb A F BamHI cgg gat ccc gac caa ggc agg ccc tcg c OR684 
m -25kb A R HindIII ccc aag ctt ggg caa gtc att tgt gtg gga cca  OR642 
m -25kb B F BamHI cgg gat ccc gat gtg ccc tcc tac atc cag t OR686 
m -25kb B R HindIII ccc aag ctt ggg cat gtg gac cta cca tgc ct OR644 
m +71Kb A F BamHI cgg gat ccc gat gaa aat gag gat gtc aca  OR690 
m +71Kb A F HindIII ccc aag ctt ggg aga tgc cag tga agt gga gat  OR691 
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m +71Kb B F HindIII ccc aag ctt gag aga cca aga ggt aca gac c OR692 
m +71Kb B R HindIII ccc aag ctt ggg cct tcc agc gga ttc aca aca OR693 
m +71Kb CL F HindIII ccc aag ctt ggc ttg gag atg cct gct gtg gc OR694 
m +71Kb CL R HindIII ccc aag ctt ggg tta aat tta cta agg atg acc OR695 
m +71Kb C F BstBI gcg ttc gaa ctt gga gat gcc tgc tgt ggc OR845 
m +71Kb C R NheI cta gct agc tag tta aat tta cta agg atg acc OR846 
m +71Kb CS F HindIII ccc aag ctt ggg caa gcc aac agc tgc agt aa OR843 
m +71Kb CS R HindIII ccc aag ctt ggg tga ggg agt tgg ttc tct cc OR844 
m +71 CTCF del F gat atc cta agt gct cac gta cag agt g OR1291 
m +71 CTCF del R gat atc ttt agg atg tgg gcc taa act g OR1292 
 
EMSA SEQUENCE 5’-3’ REFERENCE 
m SatB1 +71Kb BS F agt cca aaa taa taa aat aat aaa taa ata aat OR1271 
m SatB1 +71Kb BS R agt cat tta ttt att tat tat ttt att att ttg OR1272 
m CTCF +71Kb BS F agt cgc cag cct tca gca ggt ggc act gtt ggg OR1277 
m CTCF +71Kb BS R agt ccc caa cag tgc cac ctg ctg aag gct ggc OR1278 
m SatB1 pos BS (MAR) F agt cga cct att agt aat aac gac cta tta gta ata ac OR1140 
m SatB1 pos BS (MAR) R agt cgt tat tac taa tag gtc gtt att act aat agg tc OR1142 
 
EXPRESSION SEQUENCE 5’-3’ REFERENCE 
m PU.1 F aga agc tga tgg ctt gga gc OR1295 
m PU.1 R gcg aat ctt ttt ctt gct gcc OR1296 
Taqman mPU.1 FAM -tgg gcc agg tct tct gca cgg - TAMRA ABI 
m ßactin endogenous control 4352341E ABI 
m Actin F SYBR tga cat c cg taa aga cct cta OR926 
m Actin R SYBR cag gag gag caa tga tct tga OR927 
m gapdh F  aag ggc tca tga cca cag tc OR141 
m gapdh R cac att ggg ggt agg aac ac OR142 
m CTCF F caa ttg cac ctg tat tct gat c OR1327 
m CTCF R  gag gag gag gag gag cct gc OR1328 
m SatB1 F ctt tgg agc agc aag ttt cc OR1451 
M SatB1 R ctc tca gtg gca agg gta gc OR1452 
m/h MADD F tgg gta gca ctt ctg cat tg OR1864 
m/h MADD R cct gcc agc ttc ttc ctc ta OR1862 
h PU.1 F gga gag cca tag cga cca tta c OR727 
h PU.1 R cgg cga agc tct cga act c OR728 
Taqman hPU.1 NED - ctt cca ccc cca cca cgt gca - MGB ABI 
 h ßactin endogenous control 4326315E ABI 
h gapdh F atg ctg gcg ctg agt ac OR721 
35 
2 Materials and Methods 
h gapdh R tga gtc ctt cca cga tac OR722 
h CTCF F ttg gca aaa aga ccc aga cta t OR1556 
h CTCF R  gac acg tgt aac tgc aaa gct c OR1557 
h SatB1 F att gcc act gaa agg aat gg  OR1453 
h SatB1 R ttc gga tca tgg aga ggt tc  OR1454 
 
ACT and 3C SEQUENCE 5’-3’ REFERENCE 
ACT linker MspI gct gac cct gaa ttc gca cgt gcc tgt cgt tag cgg 
aca cag ggc gat tca c 
OR1549, (Ling et al., 2006) 
ACT linker short cgg tga atc OR1550, (Ling et al., 2006) 
ACT primer ext gct gac cct gaa ttc gca cgt gcc t OR1551, (Ling et al., 2006) 
ACT primer int gtc gtt agc gga cac agg gcg att c OR1552, (Ling et al., 2006) 
3C PU.1 pm down F outside aac agc tat tta tag atg ggt tca gtg OR1419 
3C PU.1 pm down F inside ggc agg gtt ctg ggt tga aga t OR1420 
3C PU.1+481 mm att ctg ggt tga aga tgg cga gg  OR264 
PU.1 1st intron gtt cag tgg cag gcc gaa ctc tag OR671 
mmTaq_PUP5_R_undig tgt tgc ctc cag aga ctc ct OR1775 
PU1mm Prom.out ata ggg gga gaa tgg tct ggg atg tg OR373 
PU1mm Prom. In gaa cca ggc ccc aac tgt tat ttt tg OR374 
m GAPDH2 aca cag gca aaa tac caa tg OR1661, (Spilianakis et al., 
2005) 
m GAPDH3 ctg cgc ctc aga atc ctg OR1662, (Spilianakis et al., 
2005) 
m GAPDH5 caa aac tcc tgg gtg caa g OR1664, (Spilianakis et al., 
2005) 
m URE up 1 3C locus tcc tgg aac tca ctc tga aga c OR1657 
3C PU.1-14134 mm tca ggg tgg gca aag tgt tat ctg OR267 
m –11.8kb-F ctc tgc ccg ctc tta acc tt OR1731 
3C PU.1-8286 mm ttg cct gct acc agg gag gtt g OR266 
PU.1 mm +22kb  cag gct cct caa aag gtc aag t OR802 
PU.1 mm +37kb ctc ctg acc ttg tgt ctg gga OR803 
PU.1 mm +50 kb cca aag act tgt tgg agt cat agt OR806 
PU.1 mm +71kb gct atg atc caa ggt ctt agg OR807 
m 71C ApoI 5` out aat ggc cca gct aag ggt ccc tca act OR1106 
m 71 in MspI R cta gag ttc ggc ctg cca ct OR1585 
m PUP 3C F2 tgc aga cac act tgg gac tc OR1713 
m PUP 3C F3 agg ccc ctc tct gag gtt ag OR1714 
h CC2 cct gcc ttc aga gag ttc ctg atc OR1 
h CC4 cct atg aca cgg atc tat acc aac OR2 
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h CC6 ccc aca cat taa aga gaa gga tgc OR4 
PU.1P H F ApoI tcc tgg ggt ctg gag aga gaa a OR1314 
PU.1P H RR ApoI tgt tgt tgt ttt tct ggc cca gtg a OR1311 
+94 H 5`ApoI out agc cct aat cca gtc att tgg gtg OR1170 
h 3C Apo1 +94kb R ggg aca gat tag tca tta tgc ctg g OR1318 
h 3C-TUBLa cac tac acc att ggc aag ga  OR1773 
h 3C-TUBLb cat atg tgg cca gag gga ag  OR1774 
h tub4 ctc aaa gca agc att ggt ga OR1889 
hsTaq_PUP5'  FAM – tct ctg gtg agt ccc ctc tgc tg – TAMRA ABI 
 
ChIP SEQUENCE 5’-3’ REFERENCE 
m/h PU.1 promoter F atc agg aac ttg tgc tgg ccc tgc OR41 
m/h PU.1 promoter R cca ttt tgc acg cct gta aca tcc OR42 
m PU.1 promoter endo F gat cca cgc tct cgc tat tc OR111 
m PU.1 promoter endo R gcg cta cag gaa gtc tct gg OR112 
m URE F ttt ctc ctg ctt cga ctt cc  OR91 
m URE R gag gcc tgt gtt cct tca ac OR92 
m +71 F caa gcc aac agc tgc agt aa OR939 
m +71 R agc acc gtt gtc cac agt  OR940 
m +37 F (neg ctrl) gcc ttc tag gta cta aca ggc t   OR804 
m +37 R (neg ctrl) tct ctg tat tgc cat cat ctt g OR1788 
m CTCF F (pos ctrl) ccc tcc tca ttc agg aaa ca  OR1681, (Weth and 
Renkawitz, 2011) 
m CTCF R (pos ctrl) ggc ggg agc aca tag act aa  OR1682, (Weth and 
Renkawitz, 2011) 
h PU.1 promoter F gga agg aag aaa gca gca cta OR1316 
h PU.1 promoter R ctc tga tct agc agg cta tca OR1317 
h URE F cta ggc ctg aag aga gat ctg g OR1736 
h URE R gga cag caa gga aaa gag aag a OR1737 
h +94 F gcc cat gaa gag gaa gat gag aa OR1320 
h +94 R cag aca gtg aga act ctc agg a OR1321 
h +67 F (neg ctrl) ggg gtc tat gtt ccc cag ac OR1781 
h +67 R (neg ctrl) gca ccc agc caa cag tat tt OR1782 
h CTCF F (pos ctrl) cct gac cta tat ctg gca gga c  OR1685, (Weth and 
Renkawitz, 2011) 
h CTCF R (pos ctrl) gca ccc acc ttc aat caa aa OR1686, (Weth and 
Renkawitz, 2011) 
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2.1.13 Vectors 
pBluescript 2SK (+)         Stratagene 
enhancer blocking luciferase plasmid      (Ishihara et al., 2006) 
pcDNA3.1-GFP         Promega 
pPAC4 carrying the murine PU.1 locus     (Frengen et al., 2000) 
BAC, carrying the human PU.1 locus     RP11-125 
sh-retrovirus         (Ngo et al., 2006)    
2.1.14 Software 
BLAST (NCBI) 
BLAST (Genomatics) 
Transcription factors binding site prediction (Genomatics) 
Primer 3.0 free online, primer design program  
7300 System SDS software (Applied Biosystems) real time PCR analyzing software 
CFX96 RealTime System BioRad 
Vector NTI (Invitrogen) 
Finch TV (Geospiza) 
Ensemble (genome database) 
UCSC browser (genome database and mapping of genome wide databases) 
 
2.2 Methods 
2.2.1 Mice 
Daily animal care, breeding and offspring separation was carried out in collaboration with the 
animal core facility of the Max-Delbrueck-Center for Molecular Medicine, Berlin, Germany. 
All mice were housed and bred in specific pathogen-free animal facilities. All animals 
experiments were approved by the local authorities according to the German Federal Animal 
Protection Act. 
2.2.1.1 Description of used mouse strains 
The transgenic hsPU.1 strain was generated with the help of the transgenic facility of the 
Max-Delbrueck-Center for Molecular Medicine, Berlin, Germany. Briefly, the BAC vector 
containing the human PU.1 locus and adjacent regions (total 160Kb, as illustrated in fig. ) was 
microinjected into fertilized oocytes of FVB/N mice and implanted in uteri of pseudopregnant 
FVB/N. 4 weeks after birth founder mice were identified by PCR and Southern blotting. Two 
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different lines (#1 and #55) were crossed with the PU.1 -/- strain (Klemsz et al., 1990) to 
generate hsPU.1+ / PU.1 -/- mice. These mice were used for organ collection. 
2.2.1.2 Genotyping 
Tagging of the offspring was carried out according to standard protocols. Mice were 
genotyped by locus specific polymerase chain reaction (PCR) on genomic DNA extracted 
from tail issue (see 2.2.3.1). 
2.2.1.3 Isolation of mouse organs material 
After euthanizing the mouse with CO2, the animal was rinsed in ethanol and pinned down on 
a dissecting board with the belly facing up. Mice were opened and the legs and arms were 
dissected with scissors and forceps to isolate bone marrow (BM) cells. Spleen and thymus 
were also collected. All organs were kept on ice in cold PBS until preparation. Single cell 
suspensions were generated by cut the organs in small pieces and subsequently filter them 
through a cell strainer. BM was isolated by flushing sterile the bones with PBS. 
Single suspensions were treated with ACK buffer for 5 minutes to destroy red blood cells. 
The reaction was interrupted by add PBS. 
CD19 positive cells were extracted from the single suspension cell of the spleen by CD19 
microbeads and subsequent purification by MACS columns, according to Miltenyi 
manufacture’s instruction. 
Mouse hematopoietic stem cells were extracted from the single cell suspension of the bone 
marrow by sorting for CD117 (c-kit) positive, Sca-1 positive and Lineage cocktail negative 
cells.  
Total bone marrow cells were seeded on not coated plates with conditioned medium to 
promote macrophage differentiation (DMEM supplemented with 20% FCS and 10mg/mL M-
CSF). Primary mature cells will die, whereas stem cells and progenitors will live as 
suspension cells. The only cells, which can adhere under these conditions, are in vitro 
differentiated macrophages. After 10 days suspension cells were removed, and only adherent 
cells were collected. 
For murine embryonic fibroblast (MEF), embryos were collected at 13.5 dpc from a C57/bl 
pregnant female. With curved forceps “red” tissue were removed from the body cavity (heart, 
most of blood vessels and fetal liver). Then every embryo was minced with razor blaze and 
transfered to 15mL conical tube and incubated o/n in trypsin 1X at 4°C. The next day trypsin 
embryo tissue was spin down by centrifuging, and the pellet was resuspended in complete 
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DMEM medium, pass through a cell strainer to remove not digested tissue fragments and 
seeded in 15cm cell culture tissues. MEF grow very fast and need to be split every 2-3 day to 
keep maximum confluence at 70-80%.   
2.2.2 Cell Culture and primary human cells 
2.2.2.1 Cell lines 
All indicated cells were grown in indicated media supplemented with fetal calf serum (FCS), 
glutamine and antibiotics (penicillin/streptomycin; ciprofloxacin, gentamycin and fungizone 
when needed) in an incubator at 37°C with 5% CO2. 
Human Embryonic Kydney cell lines (HEK293T), Plat_E and HeLa cells are adherent cells, 
were cultured in dishes in supplemented DMEM (10% FCS) and split every 2-3 days. 
EL-4 T-lymphoblastoma cells is a suspension cell line, was cultured in flask in RPMI 
supplemented with 10% FCS, glutamine, 4,5g/L of glucose and 50μM of ß-mercaptoethanol 
to prevent differentiation.  
Human lymphoblastom Jurkat-eco cells are Jurkat cells stable transfected with an ecotropic 
receptor, which allows infecting them with murine viruses. They were cultured in RPMI 
supplemented with 10%FCS and selection antibiotics (150ng/mL G418 for selection of the 
ecotropic receptor; 10μg/mL puromycin for selection of the plasmid containing the sh 
sequence; 20μg/mL of doxocyclin for induction of the inducible promoter) 
416B cells are a murine myeloid progenitor cell line (Dexter et al., 1979); it was cultured in 
supplemented DMEM medium (20% FCS). HL60 and U937 are human acute myeloid 
leukemia cell lines and were cultured in supplemented RPMI medium (10% FCS).  
All suspension cells were counted every 2-3 days and splitted to be maintained between 1E4 
and 1E6 cells per mL. 
2.2.2.2 Thawing, cultivating and freezing of cells 
Cells were thawed quickly in a 37°C water bath and transferred drop-wise to a tube with 
10mL medium After centrifugation (standard condition: 1200 rpm, 5 minutes, room 
temperature) supernatant was discarded and pellet was gently resuspended in 1 mL medium. 
Cells were plated in appropriate cell number on culture dishes/flasks. 
For passaging of adherent cells, medium was aspired, cells were washed once with PBS and 
incubated with 0,05% trypsin-EDTA for 5 minutes at 37°C (2mL trypsin per 10cm dish). 
Once detached, cells were harvested by adding 10mL of medium and centrifuged; supernatant 
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was discarded and pellet was resuspended in medium. Cell suspension was transferred in 
different dilutions to new tissue culture dishes. For suspension cells, they were centrifuged 
and resuspended in fresh medium. 
For cryo-preservation, cells were transferred in a Falcon tube, medium was removed and 
pellet resuspended in 1mL of freezing medium (90% FCS, 10% DMSO) and transferred to a 
cryo tube. Cryo tubes were stored in polystyrene boxes at -80°C for at least 24 hours to allow 
a gradual freezing process and to avoid crystal formation, after which they were placed in 
liquid nitrogen or at -80°C for short-term storage. 
2.2.2.3  Transient and stable transfection of cells 
HEK293T cells were transfected for transient assay according to the Turbofect in vitro 
transfection kit’s instructions (Fermentas). Briefly, 5E4 per well cells were seeded on 24-
wells plate. After approximately 24 hours 70-80% confluent wells were co-transfected with 
0,4µg of plasmid.  
EL-4 cells were transfected by electroporation according to Amaxa Cell Line Nucleofector 
Kit L (Lonza) manufacture. Cells were counted, 2E6 cells were centrifuged at 900 rpm for 10 
minutes at room temperature and the pellet was resuspended in 100µL of Cell Line 
Nuclefector Solution L. The cell suspension was gently mixed with 2µg of DNA (1,5µg of 
linearized construct to be tested and 0,5µg of pcDNA3.1-GFP plasmid, carrying neomycin 
resistance cassette) transferred into certified cuvettes (provided by the kit) and electroporated 
with Nucleofector Program C-009 (C-09 for Nucleofector I Device). 500µL of pre-warmed 
medium was added to the cuvettes and the suspension was transferred into the prepared 12-
well plate, containing 1mL of pre-warmed medium (final volume 1,5mL medium). To 
generate stable cell lines, cells were transferred to a flask in 10mL medium and selected for 
G418 sulfate resistant colonies after 48h of electroporation. Selection was performed 10 days 
long, after that viable and GFP positive cells were sorted by FACS.  
2.2.2.4 Virus production and transduction of cells  
Viral supernatants were used to stable transfect Jurkat-eco cells. Murine retroviral 
supernatants were produced by co-transfection of Plat-E cells with the retroviral construct 
(10µg), gag-pol and ecotropic env constructs as support for viral particle assemble (10 and 2 
µg respectively). Transfection was performed with Calcium Phosphate Transfection Kit 
according to manifacture. Viral supernatant were collected at 72 and 96 h after transfection, 
filtered through 0,45µm filters and either used directly or frozen and stored at -80 °C. 
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For retroviral transduction of Jurkat-Eco cells, 1E6 cells were seeded in 24-well plate in 
500µL of RMPI medium supplemented with 20% FCS and mixed with 500 µL of filtered 
virus supernatant in the presence of 8µg/mL polybrene and cultured for 24 hours. The next 
day fresh medium was added and cells were expanded.  
2.2.2.5 Patients cells and healthy donors  
AML (acute myeloid leukemia) bone marrow aspirates were collected according to ethic 
rules. All the patients presented blast infiltration of more than 80% of bone marrow total cells. 
Cells were treated with ACK for erythrolysis; this step was repeated 1 to 3 times, until when 
the cell pellet was white. Then the sample was depleted from lymphocytes by first CD3 (T 
cells) and second CD19 (B cells) microbeads according to Miltenyi manufacture’s instruction: 
briefly, cells were stained with proper microbeads, then the flow though was collected for 
further purification step, whereas the eluate (CD3 or CD19 positive cells, respectively) was 
used for testing the purity of lymphocyte depletion. The blasts content afterwards was higher 
than 95%. 
Hematopoietic stem cells were purchased from Lonza manufacture as adult bone marrow 
CD34 purified cells.  
Primary monocytes were collected from blood of healthy donors. The cells were processed as 
the AML: first erythrolysed by ACK treatment and then lymphocyte-depleted by magnetic 
beads separation. The final content of cell was mostly mature myeloid cells. 
2.2.3 Molecular Biology 
2.2.3.1 Preparation of genomic DNA: Phenol/Chloroform extraction 
DNA was extracted following standard protocols. Briefly, cells or tissue was digested with 
tail digestion buffer supplemented freshly with 10µg/mL proteinase K at 56°C o/n. Genomic 
DNA was purified by adding 1 volume of Phenol/Chloroform/Isolamylalcohol mixture (in 
25:24:1 ratio), mixed by vortexing or inverting the tubes multiple times, and centrifuged at 
high speed (13000g, 5 minutes, 4°C). The supernatant was then collected and subsequently 
mixed with 1 volume of Chloroform/Isomamylalcohol mixture (24:1) and centrifuged as 
above. The supernatant which contains nucleic acids (mostly DNA) was transferred to a new 
tube and DNA was precipitated by adding 2,5 volumes of ethanol 100%, supplemented with 
0,1 volume of NaOAc 3M pH5,2 and mixed thoroughly. After 20 minutes incubation at -20°C 
followed by high speed centrifugation (13000 g, 20minutes, 4°C) supernatant was discard and 
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pellet DNA was washed with 1mL 70% cold ethanol. After centrifugation (13000 g, 5 
minutes, 4°C), DNA pellet was air-dried until complete evaporation of ethanol. DNA was 
dissolved in water or TE buffer. 
2.2.3.2 RNA extraction 
Depending on cells numbers 2 different methods were used: for small amount of cells (less 
than 5E4) RNA was extracted using RNeasy Micro Kit according to manufacture. For bigger 
amount of cells triazol method was performed as followed. 
First, cell pellet was resuspended in 500µL Triazol by passing the solution through a 16 gauge 
needles several times. 100µL pure Chloroform was added to the tube and the solution was 
vortexed for 30 seconds and incubate 10 minutes at RT (room temperature). After 
centrifugation (13000 g, 5 minutes, 4°C) two phases can be separated: the lower phase is 
organic, meaning contains proteins and lipids, the interphase contains DNA (which can be 
separated from RNA based on the pH), and the upper phase is inorganic and contains RNA. 
So the upper phase was carefully transferred to a new tube and precipitated with 1mL Ethanol 
100% supplemented by 50µL of NaOAc 3M pH 5,2 (for less than 2E6 cells as starting 
material, also 4g of glycogen were added to visualize the pellet afterwards). After 
centrifugation (13000rpm, 20 minutes, 4°C) the supernatant was discarded and the pellet wash 
with 1mL of 70% cold Ethanol. After centrifugation (13000 rpm, 10 minutes, 4°C) 
supernatant was discarded and pellet was air-dried until complete evaporation of Ethanol. The 
pellet was resuspended in DEPC water and incubated 10 minutes at 55°C for better 
resuspension. RNA was stored at -80°C. All buffers, solutions and tips were RNase free. 
2.2.3.3  cDNA synthesis 
cDNA synthesis was performed according to Fermentas Revertaid First strand cDNA 
synthesis kit instructions, after DNase treatment (Invitrogen). Briefly, maximum of 1 µg of 
RNA was treated with DNase in the presence of RNase inhibitors for 15 minutes at room 
temperature. The reaction was stopped by vortexing, adding 1.25mM of EDTA (final 
concentration) and 10 minutes incubation at 65°C.  
Random primers provided by Fermentas BLABLA kit were annealed by 5 minutes incubation 
at 65°C, afterwards quickly chilled on ice. Then a mastermix containing proper buffer, 1mM 
dNTP, revert transcriptase and RNase inhibitors was added, and the cDNA synthesis reaction 
occurred at 42°C 1h long, followed by enzymes heat inactivation (10 minutes at 72°C).  
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Dilution and amount of cDNA used per reaction was optimized for every gene and every cell 
context. 
2.2.3.4 Polymerase chain reaction and Real Time PCR 
PCR was carried out with standard procedure. For all reactions PCRs 1,5mM MgCl2, 1x KCl 
buffer, 400nM forward and reverse primers, 400nM dNTPs and 2.5 units Taq polymerase 
were used (25µL final volume). For semi-quantitative PCR the reaction was carried out in 
50µL final volume and 12µL were taken 3-4 times; 10µL for each cycle were loaded on an 
agarose gel. For nested PCR 1µL of the first round was used as template for the second round. 
Oligonucleotides for SYBR green Real Time RT PCR were design spanning different exons 
to avoid detecting DNA contamination in the cDNA sample. Amplified PCR product were 
separated and visualized on 1-2% agarose gels containing 1µg/mL ethidiumbromide.  
For Real Time PCR 2x SYBR Green or 2x Taqman mix (Applied Biosystem) was used 
according to instructions. 7300 System SDS Software or CFX96 Real-Time System were 
used to analyze results.  
Protocols: 
All endpoint PCR: 94°C 10’’, 55-59 20’’, 72C 15’’/500bp 
All SYBR green: 94°C 10’’, 60°C 30’’ (minimum time for fluorescence reading), 72°C 10-
15’’. 
Taqman probe for expression (mm and hs actin, mm and hs PU.1): as SYBR green 
Taqman reactions for q3C (hs): 94°C 10’’, 60°C 30’’, 64°C 10’’, 72°C 10’’ 
Sybr green at Biorad machine when II temperature read was needed: 94°C 10’’, 60°C 15’’, 
72°C 10’’, II read (variable temperature according to the melting curve in order to distinguish 
SYBR grren signal of amplified product versus primer dimers or background signals which 
are usually lower) 2’’. 
2.2.3.5 Agarose gel electrophoresis 
Agarose was dissolved in 1x TAE at the desired concentration and boiled in a microwave 
until the solution was completely dissolved. Ethidiumbromide was added in the appropriate 
concentration when the temperature of the agarose gel was around 50°C. After casting the gel, 
hardening occurred within 10-30 minutes. Gel chamber was filled with 1x TAE and aliquots 
of samples supplemented with 6x loading buffer were loaded into the wells. To determine 
length of the fragments, 1Kb or 100bp ladder was used. The gel was run at 80-130V 
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depending on further applications. DNA was visualized by UV-light. Picture of the agarose 
gel was taken by BioDoc Analyzer and printed or saved as file.  
2.2.3.6 Cloning 
All used vector are listed in 2.1.13  
As general process, PCR-amplified products were purified by MSB Spin Rapace Kit and 
blunt by Klenow fragment for 1h at 37°C; blunt-ends DNA was then ligated into appropriate 
plasmids. DNA fragments deriving from plasmids were digested with specific restriction 
enzymes, gel-extracted according to Invisorb Spin DNA extraction Kit and blunt if necessary. 
Ligation was performed with T4 Ligase (NEB) using 50-100ng of the vector and 10fold of the 
insert for 2 h at RT. The ligation reaction was transformed into DH10b chemically competent 
bacteria according to heat shock standard procedure: briefly DNA was incubated with bacteria 
on ice for 20 minutes, placed in a 42°C 90 seconds long, then on ice for 2 minutes. Then, 1mL 
of pre-warmed LB medium was added to the bacteria, placed them at 37°C for 1h and then 
plated on LB-agar plates supplemented with appropriate antibiotic for selecting resistant 
colonies. Plates were incubated o/n at 37°C. The following day correct cloned vectors were 
screen by directional colony-PCR or directly by extracting the DNA according to Invisorb 
Plasmid Mini Two Kit. 
For regular subcloning of PCR products, PBluescript was EcorV digested.  
The PU.1 promoter sequence was PCR-amplified and inserted as XhoI-HindIII fragment into 
the PBluescript vector for the experiment of chapter 3.1.4. 
For luciferase enhancing blocking assay vector was used as backbone plasmid for further 
modification: briefly, all the DNA fragment to be tested were PCR-amplified with primers 
containing BamHI and HindIII overhangs respectively. The PCR products were cloned 
between the luciferase-encoding gene and the SV40 enhancers. The mutant fragments were 
inserted by triple ligation using BamHI-SacI-HindIII endonuclease. 
To test different short hairpin against CTCF a retroviral vector was used: 12 oligos as putative 
shRNA against CTCF mRNA were cloned into the retrovirus, and only the colonies resistant 
to ampicillin but not anymore to kanamycin carried the desired oligo inserted. Oligo direction 
was validated by sequencing. 
2.2.3.7 Luciferase reporter assay 
Luciferase constructs were used as reporter assay to test enhancing blocking function of 
desired DNA fragments. For this assay the DNA fragment to be tested is inserted between an 
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enhancer and a promoter, which drives the luciferase gene. Comparison between the “empty” 
vector (where no putative insulator is inserted) and the “insulator” vector provides a 
functional prove of the DNA tested. The plasmid used as control and as backbone for further 
cloning has already been described (see 2.1.13)  
Briefly, HEK293T cells were co-transfected (see 2.2.2.3) with 400ng of the luciferase 
construct and 10ng of Renilla plasmid (provided along with the kit). The next day medium 
was removed and cells were washed with PBS and then lysed according to the Dual 
Luciferase Reporter Assay System. 20% of the lysate was then analyzed with the 
luminometer. The firefly luciferase and the Renilla luciferase catalyze two different reactions. 
The light produced by the different enzyme can be red at two different wavelengths (560nm 
and 480nm respectively). The Renilla plasmid is used as internal control for transfection 
efficiency, so that the ratio between luciferase and Renilla activity guarantees for comparing 
same amount of transfected cells. 
2.2.3.8 Total and nuclear protein extract 
For Western Blot analysis was sufficient to extract total proteins (cytoplasmatic and nuclear, 
although transcriptional regulation occurs only in the nucleus). Proper number of cells (if 
possible 5E6) was spin at standard condition, washed once with PBS and centrifuged again. 
The cell pellet was resuspended with 40-400µ (depending on cell numbers: usually 2 volumes 
of cell pellet were used) RIPA lysis buffer. Lysis was performed by shaking 30 minutes at 
4°C; for bigger number of cells was necessary to sonicate 3 minutes (medium power, 30 
second on / off) to ensure all membranes to break. 
The lysate was centrifuged (13000 g, 5 minutes, 4°C), the supernatant containing all proteins 
was collected and diluted in 1:2 ratio with 2x Laemmli buffer. Proteins were boiled 5 minutes 
and then analyzed by Western Blot or stored at -20°C. Laemmli buffer is highly reducing and 
breaks disulphite bounds; by boiling complete denaturation of protein was achieved.  
Nuclear extracts were made by harvesting 1.0-3.0*E07 cells. The cells were washed twice in 
ice cold PBS (14000 rpm, 2 min, 4°C) and incubated in 400μl ice-cold buffer A (15 min, 4°C, 
shaking) in the presence of protease inhibitors (Sigma). 25μl 10 % NP 40 were added and 
mixed thoroughly. After centrifugation (14000rpm, 30sec, 4°C) the pellet was resuspended in 
50-100μl buffer C and incubated (15min, 4°C, shaking). After centrifugation the supernatant 
was flash-frozen in liquid nitrogen and stored at -80°C. 
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Whole cell lysates were done employing the TCA (1,1,1-trichloroethane) method. Briefly, 
cells were washed twice in ice cold PBS (14000rpm, 2min, 4°C), resuspended in 500μl PBS 
and mixed with 10% (v/v) TCA (15-30 min, 4°C). The lysate was centrifuged (14000rpm, 
2min, 4°C) and resuspended in 1 x SDS sample buffer and stored at -20°C. 
2.2.3.9 Western Blot Analysis 
To analysis specific protein level western blot technique was used. First of all, a 
polyacrilammide gel was made mixing liquid polyacrilammide with polimerazing agents 
(APS and TEMED) to obtain desired % of gel (6% for CTCF, 12% for tubulin or ßactin and 
PU.1).  A Western Blot gel consists in 2 phases: the stacking gel, which contain glycin which 
align all the protein at the same line and the separating gel, well proteins start to run 
specifically according to their size. 
Samples were loaded in the pockets and the gel was run for 1-2 h at 90V for the stacking gel 
and 120V when proteins reach the separating phase. Then the chamber was disassembled and 
the gel was capillary-blotted onto a previously methanol-activated PVDF membrane in the 
transfer buffer. Protein transfer was controlled staining with Ponceau solution, which binds to 
proteins; the solution can be easily removed washing with PBS the membrane several times.  
To prevent unspecific binding of the antibody to the membrane, it was incubate with 4% of 
milk (dissolved in PBS) and 0,05% of Tween 20 for 1h at RT. Milk has a highly proteic 
concentration, which will cover by ionic interaction the surface of the membrane still protein-
free (everything apart from the transferred lanes). Then the blocked membrane was incubated 
with the desired antibody (here, polyclonal antibody against CTCF and ß-actin) o/n at 4°C. 
The next day the membrane was washed 3 times with PBS and then incubate 2 hours with a 
HPR conjugated secondary antibody, which recognizes the constant part of the first antibody 
according to the species were this was raised (here, Ab α CTCF was raised in rabbit, α ß-actin 
in mouse; therefore the second antibody was (goat)-anti-rabbit and (rabbit)-anti-mouse 
respectively; all of them were conjugated with HPR, horseradish peroxidase; see 2.1.9). 
Afterward, the membrane was washed again with PBS to remove all free antibody in the 
solution and HPR activity was measured by ECL method, according to Invitrogen kit 
instructions, and developed by X-ray film. 
2.2.3.10 Electrophoresis mobility shift assay (EMSA) 
By gel shift or EMSA assay is possible to investigate in vitro DNA-protein interaction. 
Nuclear protein Extracts (NE) were mixed with oligonucleotides containing putative binding 
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site for a specific protein, loaded on a polyacrilammide gel and separated by electrophoresis. 
Due to size and charge, free DNA runs fast, whereas a protein/DNA complex is slower which 
produces the so-called “gel shift”. Moreover by adding an antibody against a presumably 
protein only, the mobility is further decreased, producing the commonly known “super-shift”. 
By radioactive labelling of DNA oligos is possible to detect different bands by 
autoradiography of the gel. Moreover, by competing the radioactive (hot) oligo with an excess 
of a not radioactive cold mutant oligo (where the putative binding sites was deleted) is 
possible to prove which base pairs are involved in the binding.  
First of all, a not denaturating polyacrilammide gel was assembled and polymerized o/n. 
Olgonucleotides were annealed producing ATGC overhangs (10 minutes at 94, 75, 50, 25, 
4°C) followed by labelling with Klenow fragment using α-32P-dCTP and 800nM of each 
dATP, dGTP, dTTP. The solution was purified by Qiagen kit to remove all free radioactive 
nucleotides and radioactivity’s yield was measured with a scintillator counter. 30000cpm 
(counts per minutes) were used per reaction. Equal aliquots of nuclear protein extracts (NE) 
were tested for binding different combinations of hot and not cold probes and with or without 
specific antibody as a.m for 30 minutes. All reactions were performed in 2x shift buffer on 
ice-cold racks. Then were loaded without loading buffer (to prevent denaturation) and 
separated by electrophoresis. The gel ran 4h long, 230V, approximately 26mA. Afterwards 
the gel was dried at 80°C for 1h. Dried gel was placed in an Amersham Hypercassete, with an 
x-ray photographic fil on top. The film was developed in a Fuji RGII photographic 
developing system. 
2.2.3.11 Chromosome conformation capture (3C) 
This technique allows the detection of two interacting chromatin fragment in vivo. 1E7 cells 
were resuspended in 10mL of proper complete medium, fixed with 2% formaldehyde (540µL 
of 37% formaldehyde) and mixed by tumbling at 4°C for 10 minutes. Crosslinking reaction 
was stopped by adding 630µL of 2M glycine (final concentration 0,1375M) and mixed by 
tumbling at 4°C for 5 minutes. Cells were pellet, washed in 10mL of cold PBS, centrifuged at 
standard conditions and the pellet was resuspended in 5mL of cold lysis buffer with freshly 
added protease inhibitors. Lysis was performed on ice for 20 minutes, afterwards cells were 
centrifuged at 600g at 4°C for 5 minutes. During lysis only cell membranes were dissolved, 
whereas the nuclei remained intact: in the following steps a digestion in intact nuclei was 
performed, in order not to destroy chromatin-protein complexes. The pellet was washed in 
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500µL of 1.2x digestion buffer (in this case, 60µL of NEB buffer 3 and 440µL of water), spun 
again at 600g, 4°C, 5 minutes. Pellet was resuspended in 500µL 1.2x digestion buffer and 7.5 
µL of SDS 20% were added. The solution was incubated in a thermomixer shaking at 900 
rpm at 37°C for an exact hour to permeate the nuclear membrane; then 50µL of preheated 
20% Triton X-100 were added to quench SDS activity and the solution was shaken for one 
more hour. By adding 800 units of restriction enzyme (in this work, BglII or ApoI enzyme 
were used) the digestion reaction was incubated at optimize temperature (37°C for BglII, 
50°C for ApoI) shaking at 900rpm.  
The next day digestion was stopped adding 40µL of SDS 20% and 20 minutes incubation at 
65°C. Then 80µL of the digestion solution was diluted in 3,7mL of 1x ligation buffer 
supplemented with 187,5µL of 20% Triton X-100 and incubated for 1 hour at 37°C (the rest 
of digestion reaction was stored at -20°C). Digested material was highly diluted in order to 
prevent intermolecular ligation and let possible only intramolecular reactions (between two 
region which really interact in vivo) The reaction was then chilled at 16°C, and 1mL aliquot 
was taken as control of not ligated material. Then 16µL of high concentrated NEB ligase was 
added in the 3mL solution and ligation was performed o/n.  
The following day 10µL/mL of proteinase K were added (also to the “no ligation” control 
aliquot) and the solution was incubated at least 4 hours @ 67°C shaking at 900rpm to 
decrosslink protein complexes from DNA and to denaturate proteins. Afterwards DNA was 
purified by phenol/chloroform extraction, and precipitated by ethanol. Pellet was resuspended 
in 50µL of TE buffer and 50ng were used for each PCR reaction. DNA material was stored at 
-20°C. 
2.2.3.12 Associated chromosome trap (ACT) 
Associated Chromosome Trap (ACT) is a modification of the 3C technique (see 2.2.3.13): by 
this method is also possible to detect inter- and intra-chromosomal interactions and co-
localization. By ACT DNA is digested first with one restriction enzyme which cuts with an 
average of 3-10Kb in the genome: ligation of these products will produce DNA circles 
consisting of two interacting DNA sequence. By a second digestion with a restriction enzyme 
which cut the genome with a high frequency is possible to linearized the previous DNA 
circles and producing protruding ends, which can be used to anneal linker oligonucleotides. 
By designing a proper primer on the query DNA sequence (in this work, PU.1 promoter) and 
the other primer on the linker is possible to amplify unknown interacting DNA sequences. 
49 
2 Materials and Methods 
PCR products were afterwards subcloned into the PBluescript vector and sequenced. 
Sequence results were BLASTed and mapped in the genome. 
Briefly, after standard 3C assay, 1µg of DNA was further digested with 20unit of MspI for 6 
hours and then the solution was by MSB Rapace Spin Kit and eluted in 50µL. 1µg of MspI-
treated DNA with mixed with linker oligonucleotides (2µL of Long Linker 10µM and 8µL of 
Short Linker 10µM), 2µL of 10x ligase buffer (NEB). The solution was denatured at 50 °C 
for 1min, and it was then allowed to cool down gradually to 10°C in a 0,5°C/min gradient. 
One µL (400 units) of T4 DNA ligase (NEB) was then added, and the mixture was incubated 
at 15°C overnight. The ligated DNA was purified by MSB Rapace Kit and eluted in 50L of 
bidistilled water. 
One µL of eluted DNA was used to perform the first PCR reaction using the PU.1 promoter 
specific primer and a linker specific primer. The PCR protocol was performed as following: 2 
min at 94 °C, 35 cycles of 94°C for 20 sec, 65°C for 40 sec, 72°C for 1 min, then 72°C for 5 
min. The first PCR product was purified by MSB Rapace Spin Kit and eluted in 50 µL of 
bidistilled water. 1µL was used for a second PCR reaction using nested primers with the same 
protocols a.m. PCR product were visualized by agarose gel, extracted by Invisorb Spin DNA 
extraction Kit, and cloned in pBluescript vector. White recombinant bacterial colonies were 
screened by colony PCR using universal primers flanking the multiple cloning site, then DNA 
was extracted by Invisorb Spin Mini Two Kit and subjected to sequence analysis. 
Sequencing results were analyzed by Finch TV software and mapped to the murine genome 
by NCBI BLAST.  
2.2.3.13 Chromatin immunoprecipitation (ChIP) 
To investigate in vivo binding of proteins to DNA Chromatin ImmunoPrecipitation (ChIP) 
was performed. In this assay proteins are covalently bound to the DNA by formaldehyde and 
then immunoprecipitated by antibody recognizing the desired protein. Then the DNA-protein 
complexes are dissembled by heat and DNA is purified and analyzed by PCR. 
ChIP assay was performed according to standard procedure. 2E7 cells were resuspended in 
10mL of complete medium, fixed with 1% formaldehyde (270µL of 37% formaldehyde) and 
mixed by tumbling at room temperature (RT) for 10 minutes. Crosslinking reaction was 
stopped by adding 630µL of 2M of glycine (final concentration 0,1375M) and mixed by 
tumbling at RT for 5 minutes. Cells were pellet, washed in 1mL of cold PBS, centrifuged at 
standard conditions and the pellet was resuspended in 400µL of ChIP cell lysis buffer with 
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freshly added protease inhibitors (1:500 diluted) and 10µM of Sodium Butyrrate (histone 
deacetylated inhibitor). The mixture was incubated on ice for 10 min, spun at 600g at 4°C for 
5min and supernatant was discarded. The lysate pellet was resuspended in 400µL of ChIP 
nuclei lysis buffer with freshly added protease inhibitors and sodium butyrate as a.m., and 
incubated for 10min on ice. 5µL aliquot was taken prior sonication. The DNA was sheared in 
eppendorf tubes in a Bioruptor Sonicator for 15 minutes by pulsing sonication 15sec on/off.  
The chromatin was submitted to a preclear process, in which rabbit serum and agarose beads 
were incubated with the chromatin at 4°C at least 1h long. This step allows cleaning the 
background of chromatin fragments binding aspecifically the Fc (constant part) of any 
immunoglobulin or the beads themselves. By spinning and taking the supernatant, cleared 
chromatin was then incubated o/n with specific antibodies as well as aspecific IgG control 
antibody by rotating on wheel at 4°C. An aliquot of 10% in volume was kept for the input 
control. The next day, beads were washed 2 times with wash buffer I, once with wash buffer 
II and twice with TE: all these steps were performed at 4°C and every washing step was 
carried out by 10 minutes incubation on a rotating wheel, spinning down the beads, remove 
supernatant. Chromatin was then eluted from the beads by elution buffer, thoroughly vortex, 
spin, and carefully take the supernatant without touching the beads. The elution step was 
repeated twice, then IP samples and inputs (diluted with same amount of elution buffer) were 
incubate o/n at 65°C after adding of 250mM filtered NaCl (final concentration) to decrosslink 
protein complexes from DNA. The next day, after 2h incubation at 45°C in the presence of 5 
µg of Proteinase K, all the samples were phenol/chloroform purified, followed by ethanol 
precipitation. 
When analyzing the in vivo occupancy starting from rare population (less than 1E5 cells), 
ChIP was performed using the LowCell ChIP kit of Diagenode according to manufacture’s 
instructions. In this thesis, this kit was used for sorted population and human primary 
material. 
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3 Results 
3.1 Identification and characterization of a novel PU.1 
regulatory element with insulating capacity 
3.1.1 PU.1 promoter interacts with lineage-specific elements  
The PU.1 promoter region is not sufficient to drive PU.1 expression alone, but relies on the 
cooperation with distinct regulatory elements. Several of these have been identified and 
characterized so far, most of which act in a lineage specific manner, (Okuno et al., 2005; 
Rosenbauer et al., 2004; Leddin et al., 2011; Zarnegar et al., 2010). However, the molecular 
mechanisms by which the PU.1 gene is maintained silenced in T-cells are still to be 
understood. In order to discover putative new regulatory elements we performed ACT 
(association chromosome trap) (Ling et al., 2006), a modification of standard chromosomal 
conformation capture (3C) (Dekker et al., 2002).  
 
 
Figure 6: schematic representation of Chromosome Conformation Capture (3C, upper panel) and 
Associated Chromosome Trap (ACT, lower panel). Grey ovals represent proteins, the grey circle delimits the 
conceptual area of DNA-protein complex. B=BglII site; M=MspI; Pp=primer on PU.1 promoter; Pi=primer on 
known interacting fragment; L=linker-based primer. 
 
As depicted in Fig. 6, by this technique it is possible to detect long-range chromatin 
interactions between a candidate region (here the PU.1 promoter) and unknown DNA 
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fragments. By subsequent linker-mediated PCR and sequencing, the new regions can be 
mapped to the genome.  
We analyzed thymocytes (T cells), where PU.1 gene is actively silenced, bone-marrow 
derived macrophages (Macs) as highly PU.1 expressing cell type and murine embryonic 
fibroblast (MEF) as non hematopoietic cells. PU.1 expression was measured at mRNA level 
in these cells, as shown in Fig.7.  
 
Figure 7: qRT-PCR showing Pu.1 mRNA level. Bars indicate values ± s.d. (standard deviation); data were 
normalized to the gapdh expression levels. Macs = bone marrow derived macrophage; T cells = thymocytes; 
MEF = murine embryonic fibroblast  
 
ACT assay is based on crosslinking protein complexes to DNA by formaldehyde covalent 
binding; to test the outcome of this initial reaction a not-crosslinked control sample was 
carried out for all three cell types. As Figure 8B shows, in not-crosslinked controls no 
interaction could be observed; on the contrary (Figure 8A), crosslinking DNA to protein 
complexes allows the detection of chromatin interactions, confirming that the chromatin 
organization is achieved with protein complexes which modulate the DNA structure. 
Interestingly, Macs and T cells show a different pattern of amplified products, whereas in 
MEF only a basic smear was detected, suggesting that no specific other genomic loci spatially 
interact with the PU.1 promoter in non-hematopoietic cells. 
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Figure 8: endpopint PCR on linked-based PCR on ACT material. A) crosslinked reaction with indicated 
cell types B) not-crosslinked controls. All the reactions were loaded on 2% agarose gel. 
 
The hematopoietic cells, represented by two different lineages, show a different interplay of 
the promoter region with other chromatin partners. This is a sign of active regulation, either to 
keep to locus active for macrophages (Macs) or repressed for T cells. In MEF cells PU.1 
expression is absent; here we didn’t detect any interacting region with the PU.1 promoter, 
suggesting that the locus is closed by different mechanisms (e.g., spread of heterochromatin).  
All amplified PCR products were extracted from the agarose gel, subcloned in the PGEM-T-
easy vector, sequenced and subsequently mapped to the genome using NCBI blast browser. 
The sequences were considered only if they met the following criteria: first, they had to 
contain the PU.1 promoter sequence; second, the mapping to the genome region had to start 
with a MspI site (in both directions); third, BglII site had to separate the PU.1 promoter 
sequence from the interacting region; fourth, BglII region flanking the PU.1 promoter were 
considered as background due to insufficient spatial distance, and the cut off for this artefact 
interaction was set to 2 BglII sites distance.  
In table 3 newly identified fragments are indicated for hematopoietic lineages. The bands we 
analyzed from MEF didn’t follow the a.m. criteria, therefore were background noise and were 
excluded. The murine PU.1 gene is located on chromosome 2, and the coding sequence’s 
(CDS) genomic coordinates are chr2:90,936,954-90,955,913 (according to USCS browser, 
assembly on July 2007; NCBI37/mm9). In macrophages, an interaction between the PU.1 
promoter and a known enhancer located 14Kb upstream of the transcription start site (TSS) as 
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well as another interaction within the same chromosome were observed. In T cells the intronic 
part of Ppard (peroxisome proliferator-activated receptor delta) gene, a metabolic gene, was 
found in physical proximity with the PU.1 promoter; moreover, two distinct chromatin 
interactions were detected in the PU.1 locus, -25 and +71Kb relative to PU.1 TSS.  
 
cells chr. BglII start BglII end region 
Macs 1 120.483.644 120.493.282 intronic: CLIP-ass. protein 1 
isoform 1 
Macs 2 
91.158.402 91.158.505 
hypothetical protein 
LOC228356 (+263 kb) 
Macs 2 90.922.792 90.925.236 Intergenic (-14 kb, URE) 
T cells 2 90.911.726 90.912.086 Intergenic (-25 kb) 
T cells 17 28.399.612 28.401.964 intronic: Ppard 
T cells 2 91.005.810 91.010.557 intronic: Madd (+71 kb) 
Table 3: genomic location of ACT-identified product. Cell type and BglII genomic coordinates are 
indicated. 
 
In this thesis we will focus on intra-chromosomal interaction in T cells, so we further confirm 
and characterize the elements found to interact with the PU.1 promoter. We first confirmed 
the -25Kb and the +71Kb element by 3C, to be sure that their detection was not a background 
PCR artefact. For this purpose we designed primers spanning the BglII site one on the PU.1 
promoter (bait) and the other on the candidate region. As control we use the bait primers 
together with primers located on the Gapdh promoter. As Fig. 9 illustrates, we could confirm 
both interaction, compared to the control locus (Spilianakis et al., 2005), where no amplified 
product was observed. 
 
Figure 9: 3C standard assay on T cells with indicated primers. 
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3.1.2 +71Kb, but not -25Kb element possesses insulting activity in vitro 
PU.1 gene must be actively silenced during physiological T cell development. Based on this 
knowledge, we investigated whether the two interacting elements could be responsible for 
PU.1 gene down-regulation. We thus tested them in reporter assay for insulator or repressor 
function, by the use of a vector containing the H19 promoter driving the firefly luciferase 
gene and a strong universal enhancer (SV40). In this assay the putative insulator should 
decrease the luciferase acitivity, when being cloned between the H19 promoter and the SV40 
enhancers. 
The -25Kb BglII fragment is almost 500bp long, whereas the +71Kb is around 4Kb long. In 
order to compare these two regions to each other and with the control insulator (Ishihara et al., 
2006), fragments on the same Kb scale were PCR amplified, spanning the -25Kb region or 
subdividing the +71Kb fragment.  
Two regions spanning the -25Kb BglII fragment in both directions were cloned in both 
orientations between enhancer and promoter to test for insulating function in vitro (Fig. 10). 
By monitoring luciferase activity there was no significant difference between negative control 
(non-insulating-control) and -25Kb fragments were observed. We therefore concluded that 
this region does not have insulator function and we excluded it from further studies. 
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Figure 10: enhancer blocking luciferase reporter assay. A) schematic representation and size of cloned 
fragment spanning the -25Kb BglII fragment. B) luciferase activity was measured after 24 hours of transfection 
in HEK23T cells and was normalized to the Renilla codifying plasmid used as internal control for transfection 
efficiency. Values of sv40 enhancer-H19 promoter construct were set to 100% and served as reference luciferase 
activity. Error bars represent S.D. of one out of at least three independet experiments  
The +71Kb BglII ACT fragment was too big to be cloned in one plasmid, so it was split in 
different regions and cloned separately: first in 3 fragments (A,B,CL) with the same size 
(around 2Kb), then in 2 overlapping ones (AC, BC), and finally narrowing down the region 
with the major insulating activity (from 71CL to 71C and 71CS).  
 
 
 
Figure 11: enhancer blocking luciferase reporter assay. A) schematic representation of tested fragments 
and relative sizes. B) relative luciferase activity of depicted constructs. Error bars represent SEM (mean standard 
deviation) of at least three experiments. 
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As illustrated in Figure 11, the fragment with best insulating activity on the SV40 universal 
enhancer is a 1.2Kb region located in the middle of the +71 BglII fragment. Importantly, the 
enhancer blocking activity was not size dependent, since fragments with similar sizes (e.g. A, 
B, CL or AC and BC) show different outcome.  
We next investigated in more detail the in vitro properties of the most important insulator 
candidate (+71C), testing it for orientation and position effect.  
 
Figure 12: enhancer blocking luciferase reporter assay testing orientation and position effect of the +71 
element. Error bars represent S.D. of at least three independent experiments.  
 
Despite the -25Kb fragment, the  +71Kb element is able to block enhancer activity on the 
promoter. Moreover, it shows two fundamental properties of an enhancer blocking insulator: 
1) is orientation independent 2) is position dependent. Both properties are illustrated in Figure 
12: when the core of the putative insulator (+71C) is cloned after the SV40 enhancer, 
luciferase activity is not repressed, indicating that in this position the +71 element has no 
activity. Whereas, when it is cloned between promoter and enhancer, it can block the inducing 
function of the enhancer on the promoter regardless its orientation. In conclusion, this in vitro 
assay suggests that the +71 element is an enhancer-blocking insulator. 
 
3.1.3 PU.1 locus chromatin interaction screen to dissect linage-specific 
local chromatin structure 
In order to investigate the nature of the interaction between the PU.1 promoter and the +71 
element in vivo we screened the whole PU.1 locus for chromatin interaction taking the 
promoter region as bait. This approach was chosen first to determine whether the physical 
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proximity detected by ACT and confirmed by 3C (see previous chapters) is a specific 
chromatin loop or just a proximity due to a closed structure along the whole locus. In second 
instance, such method gives more detailed information about the start and the end of the 
interacting fragments. Hereafter there is a summary of the experimental procedure and 
correspondent explanation of this technique; this chapter should be taken as reference and 
example for further experiments using the same technique.  
The first problem about 3C-based technologies is the missing positive control; for this reason 
every sample is related to a PAC carrying the genomic sequence of the required locus. In 
other words the reference is not standard, therefore the entity of one interaction assumes a 
meaning only when compared to other interactions or to other samples. As discussed below, 
we decided to analyze more samples and more interactions (different primer fractioning the 
PU.1 locus). 
To investigate the local chromatin structure behavior in accordance to PU.1 transcriptional 
activity, we applied the 3C technique followed by qPCR (q3C) and screened for chromatin 
interaction along the PU.1 locus in several hematopoietic populations with different PU.1 
expression levels: T cells as PU.1low lineage, B cells as PU.1intermediate=int  lineage and 
macrophages as PU.1high population (see Figure 13).  
 
Figure 13: PU.1 expression of indicated population is indicated as cDNA fold over βactin housekeeping 
gene. T cells = whole thymus extract; B cells = CD19+ splenic B cells, purified by microbeads and magnetic 
separation; BM-Macs = bone marrow derived macrophages. 
 
In order to compare different 3C samples quantitatively by RealTime PCR every step was 
controlled, according to (Hagege et al., 2007). 
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1) crosslinking efficiency: the efficiency of this reaction is practically impossible to be 
checked. A not-crosslinking control was run in parallel for the pilot experiment for all three 
lineages: no interaction was detected, confirming that without formation of DNA-protein 
complexes it is not possible to analyze chromatin structure (data not shown). 
2) digestion efficiency: it is very important to check that digestion efficiency is close to 100%. 
Moreover, different samples should be digested with very similar efficiency in order to 
compare them. Digestion efficiency was calculated by RealTime PCR as ΔCt between 
amplified product spanning BglII restriction site (PCR reaction on restriction enzyme site: 
PCRRE) in relation with a PCR product within 2 BglII sites (PCR reaction on genomic DNA 
not spanning the chosen endonuclease: PCRgDNA). These values were then related to a not-
digested sample used also for standard curve. Assuming that the primer efficiency of both of 
the two primer pairs is 2, the applied formula was: 
 
[2^ (CtstandardgDNA- CtstandardRE)] / 100 = [2^(CtquerygDNA- CtqueryRE)] / x 
 
where x is the undigested percentage of the query (3C sample).  
Digestion efficiency is then  
y = 100 – x 
% undigested % digested sample 
1,94 98,06 
T cells 2,09 97,91 
1,40 98,60 
2,67 97,33 
Macs 0,69 99,31 
1,66 98,34 
1,40 98,60 
B cells 3,08 96,92 
2,09 97,91 
11,61 88,39 neg. ex. 
0,29 99,71 PAC ctrl 
Table: 4 independent samples for every indicated population were analyzed. PAC ctrl = PU.1-PAC 
BglII digested and religated. neg. ex. = negative example.  
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3) ligation efficiency: the ligation efficiency cannot be quantified within the same samples for 
every locus in the genome. To overcome this problem, an aliquot for each sample was run in 
parallel but without ligase treatment, which allowed for a yes or no answer, whether the ligase 
worked at all. All samples (with and without the ligase) were tested for the circle formation 
reaction, meaning the ligation of digested fragments within themselves, which also represent 
theoretically the most probable ligation product.  
 
 
Figure 13: PU.1 promoter circle formation verifies the activity of the ligase. On the right, agarose gel 
showing PCR-amplified product from 3C samples, each representative for one lineage. T4 = ligated samples; NL 
= not.ligate samples; PAC T4 = positive control, here highly diluted (1pg), see bullet point 6 for explanation. On 
the left, essential graphic representation of the BglII fragment spanning the PU.1 promoter region; the primers 
used for circle PCR are indicated. 
 
4) 3C assay test: 3C samples were first tested by endpoint PCR for chromatin loops which 
were previously reporter for the Gapdh locus. This interaction is required for GAPDH 
expression, therefore can be considered as “housekeeping loop”: 
 
 
Figure 14: Long-range interation within Gapdh promoter as housekeeping loop. On the right, agarose 
gel showing PCR-amplified product from 3C samples, each representative for one lineage. T4 = ligated samples. 
On the left, graphic representation of the BglII interacting fragments on the Gapdh locus; the primers used for 
the PCR are indicated. 
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5) DNA content and salt effect: it is known that salt concentration in the DNA pellet at the 
last DNA purification step of the 3C assay can affect downstream RealTime PCR and 
interfere with spectrometer quantification of DNA content. To exclude this inhibitory effect in 
the PCR reaction and to compare samples with very similar DNA amount, samples were 
normalized by PCR for gDNA amount by serial dilution of every sample using primers not 
spanning sites of the chosen restriction enzyme.When by dilution of 10 fold the sample 
correlates with the standard curve, then no salt effect is observed (data not shown).  
6) primer efficiency: to calculate primer efficiency and to compare Ct values of different PCR 
reactions, a PAC carrying the PU.1 locus was digested with BglII followed by ligation 
reaction in small volume. This sample was used as positive control assuming that all possible 
ligation products between the BglII fragments were represented. The same sample was used 
to run a standard curve for every primer pair, by diluting the PAC control samples over 3 Log 
folds. Every efficiency was extracted by plotting the Ct versus dilution, and interpolating the 
data by adding a logarithmic trendline:  
y = mx + q 
converting the slope from log (base 10) scale to ln (base e) one: 
M= m/log10e, 
where e is the Euler’s number;  
and finally 
Eff= 10^(1/M) 
Where Eff. is the primer efficiency 
Pu.1 promoter primer +  efficiency 
-21Kb 1.88 
-17Kb 1.80 
-14,5Kb 1.88 
-11,8Kb 1.83 
+22Kb 1.83 
+37Kb 1.92 
+55Kb 1.79 
+71Kb 1.89 
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Table 5: set up of primer pairs for the PU.1 PAC control digested and religated (designed as PAC T4). 
A) schematic representation of primers closed to BglII restriction site delimitating the region tested by 3C. B) 
agarose gel shows the specificity of every primer pair used. PAC T4: positive control; PAC: negative control as 
genomic DNA not BglII and ligase treated; w: water. C) an example how to calculate the primer efficiency. For 
all PCR reactions the correlation coefficient was > 0,95. D) the table indicates primer efficiency of every primer 
pair, calculated by a standard curve diluting the PAC T4 control over 3 Log folds.  
As depicted in Figure 15, the three indicated lineages show different local chromatin structure 
spanning 100Kb around the PU.1 locus. When PU.1 gene is transcribed as in B cells and 
macrophages (Macs), we observe an interaction of the upstream cluster of enhancers, within 
which the URE shows the highest crosslinking frequency. On the contrary, the locus is 
strikingly differently organized in T cells where PU.1 is silenced: here the only prominent 
interaction is indeed the one between the PU.1 promoter and the +71 element. Interestingly, 
there is no or very low interaction in the region between these two fragments, demonstrating 
that the nature of this chromatin interaction is a loop conformation. 
 
Figure 15: q3C on PU.1 locus and surrounding genomic regions. On top of the graph genomic 
coordinates and gene bodies are depicted. Crosslinking frequency refers to the ΔCt between the PAC control and 
the query: then the highest detected value was set to 1 to obtain the relative crosslinking frequency. Cell types 
are depicted with different colors. Grey bars represent the analyzed BglII fragments and the black the PU.1 
promoter one, used as bait. The X coordinates indicate the genomic distance of the primers in relation to the 
primer on the PU.1 promoter.  
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This whole-locus screen confirms that the enhancer cluster, including the URE, is in physical 
proximity with the promoter in PU.1 expressing cells, whereas this interaction is absent in T 
cells, where the promoter loops with the +71 element.  
Are the two main interactions of the promoter with the upstream regulatory cluster URC 
(observed in myeloid and B-cells) or with the +71 element (observed in T-cells) actively 
formed during lineage commitment or are these default conformations from the stem cell 
status? To address this question, LSK (lin- Sca1- Kit+) stem cells were sorted from mouse 
bone marrow and their chromatin analyzed for interactions. Figure 16 illustrates the 2 
chromatin loops in stem cells, T-cells, B-cells and BM-Macs and MEFs as not hematopoietic 
cell line. In the stem cell compartment none of the loops could be detected in a prominent 
manner; confirming that local structure of the PU.1 locus is organized in different ways in 
various hematopoietic lineages. 
 
Figure 16: Two chromatin loops characterize specifically opposite lineages. In blue is depicted the 
interaction of the +71 element with the PU.1 promoter, in red of the URE. Error bars represent at least 2 
independent experiments. Crosslinking frequency was calculated as explained in the previous figure. The highest 
value was set to 1. 
3.1.4 Is the PU.1 promoter / +71 chromatin interaction sequence-
specific? 
In the previous chapters we analyzed the +71 element interaction with the PU.1 promoter in 
the endogenous locus. We next asked whether the DNA sequences are sufficient to form the 
a.m. loop also when not located on the same chromosome. For this reason we used a mouse 
strain previously created in our lab: we inserted the human PU.1 locus by injecting a BAC 
(bacterial artificial chromosome) into murine oocytes (Fig. 17), resulting in transgenic mice 
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which carry both murine and human PU.1 copies. By crossing these offspring into the PU.1 
knockout background, we could demonstrate that the human locus can rescue the PU.1 
lethality of PU.1KO mice (Leddin et al., 2011).  
 
Figure 17: genomic region contained in the BAC injected in oocytes. The total length is around 160Kb 
and the integrity of integrated BAC was confirmed by several Southern Blot probes (data not shown). 
The human PU.1 protein resembled qualitatively the tissue-speci fic expression of the murine 
counterpart. The transgenic BAC doesn’t contain the region homologous to the +71 element. 
In the human genome this element is located +94Kb downstream the PU.1 TSS. We therefore 
hypothesized that the expression of the human PU.1 could be silenced during T cells 
development by forming the previously identified loop between the human copies and the 
endogenous +71. For that purpose, we performed 3C on thymocytes on this mouse strain, as it 
is possible to distinguish the endogenous (murine) from the transgenic (human) sequences by 
using a different restriction enzyme, suitable for the human promoter (ApoI rather than BglII 
as in the previous assays).  
This result demonstrates that the chromatin interaction takes place regardless of the genomic 
position, and that the DNA sequences by themselves contain all the information needed to 
form the chromatin loop. 
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Figure 18:  Interaction between human PU.1 promoter and murine +71 element. A) schematic 
representation of the analyzed ApoI-fragments with the primers used for PCR on 3C material. B) agarose gel 
showing PCR products detecting, from left to right, the murine +71 circle, the interaction between human PU.1 
promoter and murine +71 element in two genomic direction. T4=3C sample; NL=No Ligase control. The ladder 
is indicated. The star on the second panel indicates the specific product. C) the table summarizes the displayed 
amplified products with their relative size and genomic location.  All PCR products were verified by sequencing.  
3.1.5 The PU.1 promoter / +71 element loop regulates PU.1 expression 
Enhancer blocking insulators are usually located between an enhancer and a proximal 
promoter to control the functional interaction between both elements (West et al., 2002). One 
of the current models explains enhancer-blocking activity by a direct interaction of an 
insulator with an enhancer or a promoter, leading to disruption of the promoter-enhancer 
interaction and gene inactivation (reviewed in (Raab and Kamakaka, 2010)). Here, we 
identified a genomic element with insulator properties that is located far outside of the PU.1 
enhancer/promoter cassette, but can loop to the promoter in a cell-type specific manner.  
We tested the hypothesis that the interaction of the insulator with the promoter blocks 
endogenous PU.1 expression. For this aim, we generated stable T cell lines carrying 
66 
3 Results 
transgenic PU.1 promoter fragments. The idea behind this approach consists in 
overexpressing exogenous copies of the PU.1 promoter which will interact with the +71 
insulator, disrupting its interaction with the endogenous PU.1 promoter (Figure 19).  
 
 
Figure 19:.Concept of sequestering the endogenous loop approach. A) Flow chart of generation of stable 
cell lines. B) schematic conformational change of loop formation from endogenous to exogenous PU.1 promoter. 
in red: exogenous promoter, in grey: endogenous promoter, in green: +71 endogenous insulator. Blue and grey  
ovals: protein complex forming the chromatin interaction.C) copy number of different pools by qPCR shows the 
heterogeneity of the pools. For GFP, a standard curve was performed related to a transgenic mouse model 
containing only one copy. For the PU.1 promoter, the values were normalized to 1 related to normal genomic 
DNA content (2n=1) 
Lymphoblastoma EL-4 cells were employed as T cell line, because they express low amount 
of PU.1. EL-4 cells were transfected with a plasmid carrying 2,1Kb of the PU.1 promoter 
region or the empty vector as control. In order not to have an additional promoter in the same 
plasmid, a vector containing neomycin resistance cassette and coding for GFP as reporter was 
co-transfected in a ratio of 1/10 compared to the PBluescript empty or the exogenous PU.1 
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promoter: this vector allowed us both to select for antibiotic resistance and to follow the 
selection process by GFP signal in FACS analysis (data not shown). Different pools were 
generated and tested for heterogeneity by quantitative RealTime PCR, detecting either the 
GFP coding sequence, present in both, or the PU.1 promoter using primer spanning both 
endogenous and exogenous copy. 
To validate the system, it is required to detect the interaction between the exogenous promoter 
and the endogenous +71 insulator. It is possible to distinguish between the two promoters by 
using different restriction enzymes in 3C assay: while BglII is the enzyme of choice for using 
the endogenous promoter as bait, because this fragment contain the region upstream the PU.1 
TSS, ApoI is suitable for the exogenous one, because its restriction site are contained in the 
backbone of the pBlue plasmid. On the other hand, the +71 element can be analyzed by both 
digestions, which span over the insulator core with similar size fragments, 4Kb for BglII 
digestion and 6Kb for ApoI (as ligation efficiency might also depend on length of ligation 
partners) Figure 20 shows an exemplarily interaction pattern of cell lines containing the 
PU.1p-Tg (transgenic PU.1 promoter sequence) compared to the control lines. For this 
endpoint PCR, the PAC control was adapted to the context: the mPU.1-PAC (PAC carrying 
the PU.1 locus) as well as the two plasmids used to generate the stable cell lines (pBlue PU.1-
Tg and pBlue) were digested by ApoI. Then the digested PAC was separately religated in 
equimolar ratio to every of the two plasmids. In the bottom panel, PCR detecting the circle 
formation around endogenous promoter was performed as control for genomic DNA content 
as well as for the 3C procedure: cell lines with the exogenous promoter or the empty control 
show similar intensity of the amplified product. Importantly, the transgenic promoter copies 
interact specifically with the endogenous +71 element, depicted in the upper panel. Along the 
PU.1 locus we also controlled that this interaction is unique and specific, as confirmed by the 
testing interaction between the exogenous promoter and a BglII fragment located +55Kb 
downstream the PU.1 promoter (middle panel). In contrast, cell lines carrying the empty 
vector (pBlue) didn’t show any of these interactions. The PAC controls verified that the PCR 
products were specific: in fact, the control not including the exogenous promoter plasmid 
didn’t show interaction within this fragment. All the PCR amplified products were verified by 
sequencing.  
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Figure 20: the exogenous PU.1 promoter interacts with the endogenous +71 element. PU.1p-Tg = 
exogenous promoter carrying cell lines. pBlue empty = control cell lines with empty vector. 3rd lane = control 
for PU.1p-Tg, 4th lane = control for pBlue empty lines. 3C assays was based on ApoI digestion. 
 
We finally tested the different pools of both genotypes for PU.1 expression by qPCR as well 
as for the endogenous loop formation by 3C. Interestingly, we could demonstrate that in the 
transgenic cell lines carrying the PU.1p-Tg integrated into the genome the loop between 
endogenous promoter and +71 element is significantly reduced to approximately 20% 
compared to the control cell lines (Fig. 21A). Intriguingly, PU.1 expression is increased by 4-
fold upon loop formation reduction (Fig. 21B). 
By this transgenic approach, we could show that the exogenous promoter sequence is able to 
compete with the endogenous promoter locus, interacting and therefore sequestering the +71 
element from its physiologic function. The consequent reduction of endogenous loop 
formation correlates with an enhanced PU.1 transcription. This is shown both by increased 
histon acetylation of the PU.1 promoter, a hallmark of active transcription, as well by cDNA 
PU.1 level. 
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Figure 21: reduced loop formation corresponds to PU.1 upregulation. A) q3C on cell lines containing the 
empty vector pBlue compared to transgenic promoter PU.1p-Tg. Crosslinking frequency was calculated as ΔCt 
between every sample and the PU.1-PAC control; average of pBlue cell lines was set to 1 to obtain relative 
crosslinking frequency. P value is indicated. B) qPCR with exon spanning primers on PU.1 cDNA. pBlue mean 
expression was set to 1. C) H3K9Ac in vivo binding on the PU.1 promoter. Bars show the average of 3 
independent pools each. Every enrichment was first calculated as fold over correspondent control IgG antibody, 
then pBlue average was set to 1.  
 
Taken together, these data provide strong evidences for a functional role of the newly 
discovered genomic insulator that represses PU.1 gene by chromatin looping. 
 
3.2 Chromatin organizer proteins mediate the PU.1 
promoter/+71 chromatin loop 
3.2.1 CTCF and SatB1 bind to the PU.1 promoter region and to the +71 
insulator 
In the previous chapter we identified and characterized a novel element responsible for PU.1 
gene regulation in T cells. We showed that the +71 element is an insulator, which physically 
contacts the PU.1 promoter. In this chapter we focus on the proteins  that are involved in the 
formation of this chromatin loop. Bioinformatic screening was performed on the +71 element, 
using free online web tool as Genomatics and the insulator database. The list of most 
prominent candidates was obtained by applying the following criteria: 1) the proteins should 
be expressed in T cells, 2) its binding site should be conserved between mammalian species, 
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3) the putative protein should dimerize and/or be able to form chromatin loops. The outcome 
of this screening for transcription factor binding sites revealed CTCF and SatB1 as good 
candidates. Both are chromatin organizers and remodelers at local level as well as in high 
order chromatin structures, such as heterochromatin formation or chromosome territories 
organization. Moreover, both proteins are highly expressed in T cells and their function is 
required for proper T-cell development, as was demonstrated in loss-of-function models (KO 
mice).  
SatB1 is a 100Da protein with multiple functional domains. Among them, a BUR-binding 
domain is necessary for DNA recognition sites, an atypical homeodomain and a PDZ domain. 
All these domains are necessary to confer SatB1 high specificity to the BUR DNA sequences, 
and to distinguish them from any AT-rich DNA sequences (Burute et al., 2012). CTCF 
(CCCTC binding factor) is nowadays recognized as the main “chromatin weaver” of the 
genome, binds the DNA via zinc finger domains (it contains 11 of them) as monomer, dimer, 
tetramer, heterocomplexes with homologues protein like BORIS (Phillips and Corces, 2009). 
Predicted binding sites of these nuclear factors need to be confirmed experimentally since the 
core sequence has not been fully characterized so far. For that purposes, nuclear extracts from 
murine thymocytes were first tested by gel shift assay for the capability to bind the +71 
element. 
As depicted in Figure 22, binding of CTCF and SatB1 to the +71 was confirmed. To test 
whether a band is the specific result of the protein binding to the radioactively labelled oligos 
representing the putative binding site, different not labeled oligos were co-incubated in a 
molar excess ratio. The cold probe contains the same sequence as the labelled oligo, so here 
all bands disappear. To exclude unspecific bands known binding sites for CTCF or SatB1 
were used as competing oligos. Thus, in these lanes the specific band could not been detected. 
Importantly, incubating nuclear extracts with the labeled binding site oligo and the antibody 
targeting the candidate protein (here only displayed in the SatB1 EMSA), a super shift was 
observed, which could occur only in the case that the ternary complex 
(oligo+protein+antibody) has formed. The specificity of the antibody was compared using an 
unspecific antibody (IgG) which does not bind to the binding candidate, and therefore does 
not produce any ternary complex. This is shown in the last two lanes of each gel shift. In 
conclusion, CTCF and SatB1 are indeed able to bind in vitro the identified binding sites.  
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Figure 22: The +71 element is bound by chromatin nuclear factors in vitro. A) EMSA with nuclear 
extracts from murine thymocytes shows that CTCF can bind the +71 element. – and + represent absence or 
presence of indicated component in the binding reaction. Free probe, CTCF binding shift and super-shift with a 
CTCF antibody (s.s) are displayed. B) EMSA for SatB1 binding site on the + 71 element.  
 
Next, we tested the +71 element and the PU.1 promoter region for in vivo binding of CTCF 
and SatB1: it could happen in fact, that the sequence is bound in vitro, especially by abundant 
proteins like CTCF and SatB1 in thymocytes nucleus, but not living cells. Chromatin 
immunoprecipitation (ChIP) assay was thus performed on three different cell types, T cells, B 
cells and macrophages, which represent different PU.1-expressing lineages (see chapter 
3.1.3). In parallel, also the acetylation on lysine 9 of the histone 3 (H3K9Ac) was investigated 
by ChIP on the PU.1 promoter region: H3K9Ac is a hallmark of active transcription because 
it is involved in recruiting the RNA polymerase II activated complex to the promoter of a 
gene. Both CTCF and SatB1 bind their relative binding sites within PU.1 promoter and +71 
element. Figure 19 illustrates the occupancy of CTCF (a), SatB1 (b) and H3K9ac (c) in the 
indicated DNA regions. Interestingly, CTCF and SatB1 bind the PU.1 promoter and the +71 
element in a T cell specific fashion, suggesting a nice correlation between their occupancy 
and the repressive chromatin loop. Histone acetylation confirms at epigenetic level that the 
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promoter region is transcriptionally active in B cells and macrophage lineages, reflecting the 
intermediate and high level of PU.1 protein, respectively. CTCF binds the DNA very 
frequently with very variable affinity, therefore is important to check the threshold between 
background and reliable enrichments. To control the chromatin immunoprecipitated by CTCF 
antibody, one known binding site (on the c-MYC gene) was amplified as positive control, 
whereas a region located +37Kb downstream the PU.1 promoter was used as negative control. 
The positive control for SatB1 binding (Cai et al., 2003) was run to test the efficiency of the 
antibody: for this protein, none of the commercially available antibody is working for in vivo 
binding assay, and here we used a friendly gift of the Kohwi-Shigematsu’s lab, who raises 
their own antibody. 
 
Figure 23: ChIP assay on T cells (black bars), B cells (grey bars) and myeloid cells (white bars). T cells 
were extracted from thymocytes, B cells were purified by magnetic separation from spleen using a CD19 
antibody and myeloid cells were sorted as Ly6c+ MCSFR- from bone marrow suspension. In all panels, 
enrichment is displayed as fold over IgG control. Crosslinked chromatin was immunoprecipitated with antibody 
against A) CTCF, B) SatB1 and C) H3K9ac. 
 
3.2.2 CTCF mediates the chromatin loop formation: a loss in function 
approach 
To test whether the binding of CTCF to the insulator and the PU.1 promoter region is 
involved in the chromatin loop formation between these regions, a knock-down approach was 
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used. CTCF was shown to be necessary for T cell development (REF.). Since the deletion of 
CTCF is lethal, an inducible knock-down system is required, an inducible T cell line was 
used. We therefore engineered Jurkat cells (human lymphoblastoma cell line) by first 
transfecting with a plasmid encoding for a mouse ecotropic retroviral receptor, increasing the 
susceptibility of cells to infection with retroviral vectors of ecotropic host range. In this way 
mouse retroviral virus can easily be produced in vitro and afterwards used to infect Jurkat 
cells with high transduction efficiency (30-80%); moreover, by this system harder to handle 
human lentivirus can be avoided. The resulting Jurkat-eco cells were then transduced with a 
TET-on system (Ngo et al., 2006), and finally with vectors containing shRNA against the 
CTCF mRNA.  
 
Figure 24: flow chart of TET on/off for inducible cell line.  EcoR: ecotropic receptor. 
 
Since Jurkat cells are human cells, it was first necessary to test the homologue region to the 
murine +71 element had insulating properties. For that, the luciferase enhancer blocking assay 
was performed and indeed the +94Kb element (human insulator, located 94Kb downstream 
the human PU.1 promoter) was ablating the SV40 enhancer function on the promoter.  
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Figure 25: +94 element acts as insulator in vitro. Enhancer blocking assay indicates that the +94 element 
leads to a reduction of luciferase activity. Thus the +94 element is an insulator like the murine +71 homologue 
region. 
 
It has been shown for several discrete regulatory elements (Wilson et al., 2011a) as well as at 
genome wide scale (Schmidt et al., 2012a)that conserved regions are coding for more vital 
function. So it is interesting that the +71 (mouse) or +94 (human) insulators exert the same 
functionality: this allows to switch easily between the two species for technical reasons, and 
also suggests that the insulating effect of these region located downstream the PU.1 promoter 
represents an evolutionary conserved mechanism to regulate the PU.1 gene in T cells. 
After screening 12 different shRNA constructs (data not shown) for CTCF downregulation, 
lines #2 and #12 were chosen for the best knock down (kd) of CTCF after 72 hours of 
induction. Importantly, these lines did not show increased cell death in 72 hours compared to 
the scramble (sc4) control line: we therefore assume, that the following results are indeed 
CTCF-level dependent rather than apoptosis effects. In Figure 26, we confirmed the 
downregulation of CTCF at protein level. In these induced cells, the loop between PU.1 
promoter and +94 element was measured by quantitative 3C assay, as explained in chapter 
3.1.3. The chromatin loop formation decreased down to 20-40% in a reproducible way (in 
three biological independent experiments), strongly correlating the level of CTCF and the 
insulating loop. 
Since CTCF plays distinct and crucial cellular functions, it is hard to distinguish whether this 
effect is direct or indirect. The scramble cell lines controls only for side effect of the shRNA 
vector, but not for a general knock-down of CTCF. In other words,  is the reduction of the 
insulating loop formation a specific effect or are all chromatin interactions affected upon 
CTCF downregulation? Since “positive” and “negative” controls are impossible to be defined, 
this issue was addressed by measuring a loop of a housekeeping gene as positive control, in 
this case in the promoter of the TUBULIN gene (Hou et al., 2010), which entity didn’t 
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significantly change, and which protein level also doesn’t change as shown in the western blot 
(Fig. 26A, third panel). On the other side, a region between the +94 element and the PU.1 
promoter, which doesn’t loop with the promoter, was chosen as negative control. Upon 
downregulation of CTCF this chromatin interaction was still not detectable (data not shown).  
Hence, the reduction of the +94/PU.1 promoter loop depends on CTCF levels, suggesting that 
CTCF physically mediates this chromatin interaction. 
 
Figure 22: Loop formation in kdCTCF human cell lines. A) western blot on total extracts confirm the 
downregulation of CTCF at protein level compared to the tubulin loading control. B) Upon kd of CTCF, q3C on 
PU.1 promoter / +94 element loop is reduced. On the contrary, housekeeping chromatin loop did not vary in C).  
 
To investigate whether the PU.1 gene is directly regulated by the chromatin loop, PU.1 
expression was measured at transcript level; but, as shown in Figure 27A, mRNA level of 
PU.1 is not affected upon CTCF downregulation. Thus, the disruption of the insulating loop is 
not sufficient to activate the PU.1 locus in Jurkat cells; but several epigenetic mechanisms 
could occur concomitantly, and affecting only one of these (the high order chromatin structure 
at local level) might be not sufficient to reprogram the regulation of the gene. Supporting this 
hypothesis, histon acetylation did indeed increase in kdCTCF lines (Figure 27B) compared to 
scramble Jurkat cell line, indicating that the PU.1 promoter status is prone to be activated. 
Another epigenetic mechanism, which is known to maintain PU.1 gene silenced, is DNA 
methylation at the promoter and upstream regions. It has been shown that upon treatment of a 
demethylating agent (5-AZA) PU.1 promoter loses its methylated status resulting in 
upregulation of the PU.1 transcript (Amaravadi and Klemsz, 1999). Therefore kdCTCF lines 
and scramble control were treated with low concentration of 5-AZA for 36 hours, and both 
CTCF and PU.1 levels were measured at mRNA level (Fig. 27C and 27D): while CTCF 
levels were not affected, PU.1 expression rose proportionally more in the kdCTCF lines. This 
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result indicates that the loop formation is mediating by CTCF, that the PU.1 locus is silenced 
by different and synergistic mechanisms and that upon demethylation of the promoter the 
silencing effect of the chromatin loop in kdCTCF lines was reduced. 
 
Figure 27: PU.1 expression upon CTCF downregulation. All 4 panels’ results are derived from the same 
representative experiment, which was repeated 3 independent times. In all panels, sc4=scramble cell line, #2 and 
#12 are kdCTCF cell lines. A) PU.1 transcripts, relative to gapdh expression, were normalized to the scramble 
control. B) ChIP versus H3K9ac in indicated cell lines. Enrichment was calculated as fold over IgG control 
antibody. Data were afterwards normalized for the scramble’s one. C) CTCF expression normalized for the not 
treated scramble line. NT= not treated. AZA= 36h treatment with 1µM of demethylating reagent 5_AZA. D) 
PU.1 mRNA normalized for the scramble cell line, not treated with AZA, as shown in panel A. 
 
Does CTCF change its occupancy when downregulated? Figure 28A illustrates CTCF ChIP 
assay on kdCTCF lines. The positive control PCR demonstrated that is technically possible to 
detect very low level of CTCF (even in the mentioned cell lines, where CTCF is drastically 
downregulated); in fact, the enrichment doesn’t significantly varying between scramble and 
kd. Notably both the PU.1 promoter and the +94 insulator are bound by CTCF in a level-
fashion way. Still, the results are hard to interpret since CTCF could exploit its function by 
binding with different affinity, meaning that the observed outcome could have biological 
functions or not (Splinter et al., 2006). To support our hypothesis that the loop is directly 
mediated by CTCF to silence PU.1 gene, we decided to employ the previous established EL-4 
cell lines for the sequestering experiment. In these cell lines we observed a reduction of the 
loop without changing CTCF expression; investigating CTCF binding in this setting will thus 
provide the direct correlation between CTCF occupancy and loop formation. We designed 
primers, which distinguished the endogenous promoter region from primers spanning both 
endogenous and transgenic copy. As control we monitor the enrichment on the mouse +71 
element. Interestingly, while the binding of CTCF on the insulator remained invariant, CTCF 
occupancy didn’t vary at the insulator level, whereas it increases in the transgenic cell lines at 
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the overall PU.1 promoter (endogenous plus transgenic) compared to the specific PU.1 
promoter (endogenous only). These results suggest that CTCF occupancy shifted from the 
endogenous to the transgenic promoter region (Fig. 28B).  
Taken together, in this chapter we demonstrated that the loop is mediated by CTCF, which 
binds to the insulator and promoter region. This chromatin loop contributes to silence PU.1 
gene in T cells. 
 
Figure 28: CTCF binding correlates with the insulating loop formation. A) CTCF ChIP on kdCTCF cell 
lines compared to the scramble control. The enrichment of CTCF binding is shown as percentage of the input. 
Error bars indicate S.D. of one representative experiment. Experiments were performed at least on three 
biological independent experiments. Positive and negative controls are on the MYC promoter gene and +55Kb 
downstream the PU.1 promoter, respectively. +94 element and promoter region are indicated. B) CTCF ChIP on 
mouse EL-4 cell lines comparing the mock control versus the stable cell lines containing transgenic copies of the 
PU.1 promoter. Enrichment is illustrated as fold over IgG negative antibody control, error bars represent S.D. 
between three pools each genotype of one representative experiment. Genomic region amplified by PCR are 
indicated: in the first lane, primers spanning only the endogenous PU.1 promoter region are used, whereas in the 
second primers amplifying a common region within the 2,1 Kb of he transgenic promoter and the endogenous 
one are indicated. The third lane represents enrichment at the murine +71 element.  
 
3.2.3 Chromatin architect SatB1 does not mediate the insulating loop 
In chapter 3.2.1 it was shown that SatB1 binds both at promoter and insulator level. SatB1 is 
essential for proper chromatin architecture, especially for establishing chromosome territories. 
Moreover, SatB1 is crucial for T cell development; its loss compromises T cell differentiation 
at the level of gene regulation and at nucleus architecture level (Galande et al., 2007). During 
T cell differentiation SatB1 undergoes to gene downregulation, so it would be interesting to 
follow the loop formation during T cell development. This experiment would require too 
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many undifferentiated cells; thus, the same inducible loss in function approach as illustrated 
in the previous chapter was applied for SatB1. To efficiently knock down SatB1, 18 different 
shRNA constructs were tested in Jurkat cells and transcript level was measured after 48 hours 
(data not shown). The best two cell lines were selected for further analysis, named #15 and 
#18, as illustrated in the western blot in Figure 29A. Upon SatB1 downregulation, confirmed 
both at mRNA and at protein level, PU.1 expression did not rise (Figure 29B). Also histon 
acetylation did not change, suggesting that knocking down SatB1 did not modulate the histon 
code at the promoter level (Figure 29C). For that reason, 5-AZA treatment effect is not shown 
here, since no differences in PU.1 levels was observed between scramble and kdSatB1 lines.  
 
 
Figure 29: Validation of inducible Jurkat lines to knock down SatB1. A) Downregulation of SatB1 at 
protein level compared to loading control. In the upper lane IP against SatB1 is shown; in the lower one, tubulin 
control. Sc4 = scramble; #15 and #18 are the most effective shRNA used. B) PU.1 mRNA level in indicated cell 
lines. Values are calculated as ΔCt related to GAPDH levels, then normalized for the scramble control. C) ChIP 
against H3K9ac: enrichment is depicted as fold over IgG and then normalized to the scramble control. 
 
Interestingly, insulating loop formation increased upon knock down of SatB1 (Figure 29A). 
Chromatin loop at the TUBULIN promoter was used as housekeeping control and did not 
significantly change, indicating that the differences observed in the +94 / PU.1 promoter loop 
were not an artefact of downregulation of SatB1. As mentioned before, SatB1 downregulation 
occurs during T cell maturation; the increase of the chromatin loop could be therefore 
explained as a maturation of Jurkat cells with lower level of SatB1. Since CTCF levels were 
also increasing upon kd of SatB1 (Figure 30C), the increased chromatin loop could be also be 
a consequence of higher CTCF expression. Hence, in order to understand whether SatB1 
directly mediates the loop, in vivo studies would be necessary; for that purpose, a valid SatB1 
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antibody would be required. For all these reasons, we did not investigate the role of SatB1 
further in this thesis. 
 
Figure 30: Loop formation upon kdSatB1. Relative crosslinking frequency is depicted for q3C assay 
detecting in A) the chromatin loop between +94 element and PU.1 promoter and in B) the housekeeping loop on 
the TUBULIN promoter in indicated cell lines. C) CTCF expression was measured at transcript level and 
represented as fold of the scramble control. 
 
3.3 Acute myeloid leukemia displays the insulating loop 
between insulator and PU.1 promoter  
In the previous chapters a lineage specific chromatin loop was described to silence the PU.1 
gene in T cells, but not in B cells or myeloid cells where PU.1 is expressed at higher levels; 
the T cell specificity of the loop was investigated in physiological hematopoietic populations, 
where PU.1 is required for myeloid differentiation and its silencing is necessary for T cell 
development.  
But what happens to the local chromatin structure in a leukemic context? It has been shown in 
mouse models that altering PU.1 levels in distinct lineages can lead to different leukemia. In 
human patients, PU.1 dysregulation occurs very often in Acute Myeloid Leukemia (AML). 
AMLs harbor a block in myeloid differentiation, in which leukemic blasts display lower 
levels of PU.1 in respect to mature myeloid cells.  
This chapter investigates the AML context of PU.1 locus chromatin structure. 
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3.3.1 Insulating T cell specific loop adopted by AML cell lines 
To test the hypothesis whether PU.1 downregulation in AML can be accomplished by the 
insulating chromatin loop, two AML cell lines were tested for the loop formation: HL-60 and 
U937, promyelocytic blasts and histiocytic lymphoma with monocyte morphology, 
respectively. Two epithelial cell lines (non hematopoietic) were chosen as negative controls, 
HeLa cells and HEK293T cells, deriving from an adenocarcinoma and embryonic kidney, 
respectively. As illustrated in Figure 31, PU.1 expression, insulating loop formation and in 
vivo CTCF binding were investigated. This were in line with the experiments of previous 
chapters, where we showed a strong correlation between the transcriptional silencing of PU.1 
gene, the formation of the CTCF-dependent insulating loop in mature T cells.  
 
Figure 31: Investigating the insulating loop in AML cell lines. A) PU.1 mRNA levels as fold of GAPDH 
expression. B) q3C detecting the +94/PU.1 promoter loop on indicated cell lines depicted as crosslinking 
frequency. All the values were normalized for the highest level, here in HL-60 cells. C) ChIP assay against 
CTCF: enrichment was calculated as fold over the control antibody IgG. Primers are spanning the human 
insulator region. 
 
In tested AML cell lines PU.1 expression is very high compared to not hematopoietic cell 
types or T cell line, but is still lower compared to peripheral blood myeloid cells (there are no 
macrophages in the blood, just monocytes), which is at least 10 fold higher (Fig. 31A, data 
not shown). Notably, the chromatin loop could be detected also in AML lines, where PU.1 
regulation is altered (Fig. 31B); and interestingly, CTCF binds to the insulator region as in T 
cells (Fig. 31C). From these results it could be observed that in an AML context the local 
chromatin structure can mimic conformations specific for another lineage. 
81 
3 Results 
As conclusion, AML lines were a suitable model for further experiments, and within them 
HL-60 cells were selected as a model cell, since they harbor the chromatin loop with higher 
frequency and lower PU.1 levels.  
 
3.3.2 Chromatin conformation of the PU.1 locus shifts from inactive to 
an active status upon induced differentiation 
It has been reported that the HL-60 cell line can be differentiated into mature monocytes upon 
several stimuli, like phorbol myristic acid (PMA, TPA), retinoic acid and butyrate, 
hypoxanthine, dimethylsulfoxide (DMSO, 1% to 1.5%), actinomycin D. Here we made use of 
this knowledge to track the chromatin conformational change upon induced differentiation. 
This approach would let us monitor the local structure of the PU.1 locus when an AML cell 
line is forced toward terminal differentiation and therefore forced to escape from the 
malignant context of leukemia. HL-60 cells were thus treated for 72 hours with TPA, then 
only adherent cells were collected and analyzed for expression, and chromatin conformation.  
 
Both CTCF and PU.1 level were measured as transcript (Fig. 32 A and B): while CTCF didn’t 
vary, PU.1 transcript increased compared to not-treated cells. Thus we can conclude that the 
during the induced differentiation PU.1 gene regulation. In this set up, the local chromatin 
structure of the PU.1 gene turned from a repressive state to a more active one (Fig. 31 C and 
D). While the insulating chromatin loop between the insulator and promoter drastically 
decreased, the loop of the promoter with the upstream regulatory cluster (URC) increased. 
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Figure 32: Chromatin characterization of HL-60 upon induced monocytic differentiation. A) cytospin 
stained with May/Grünewald-Giemsa after 72 hours of TPA treatment shows macrophage and granulocyte 
morphology compared to the solvent not-treated control (N.T.). Cells were differentiated in 3 independent pools. 
B) CTCF and C) PU.1 transcript as fold over GAPDH expression. Not-treated control was set to 1. D, E) q3C 
assay in not-treated cells and 3 independent pool of HL-60 TPA treated: on the left the repressive loop between 
+94 insulator and PU.1 promoter is depicted, on the right between the same promoter and the upstream cluster of 
enhancers (URC). Crosslinking frequency was calculated as explained in chapter 3.1.3 and not-treated control 
value was set to 1.  
3.3.3 Chromatin insulating loop in AML patients 
In the previous chapter it was shown that AML cell lines display the +94 / promoter loop, 
found before only in T cells. This result was a prerequisite before analyzing primary cells 
from AML patients. As already mentioned in chapter 1.3.2, acute myeloid leukemia are 
extremely variable in regard to differentiation stage block, dysregulation of oncogene/tumor 
suppressor genes, heterogeneous surface markers’ pattern, etc. It is therefore challenging to 
purify only the leukemic blast from bone marrow aspirates: they do not only contain several 
cell types, but even more strikingly their distribution could dramatically vary from patient to 
patient. To overcome this issue, a negative selection approach was applied, trying to deplete 
the bulk of bone marrow cells from undesired lineages: red blood cells were eliminated by 
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basic osmolitic buffer (ACK buffer), lymphocytes were excluded by magnetic beads coupled 
with antibodies against pan T and B cell determinants (CD3 and CD19, respectively). The 
remaining cells comprised cancer blasts, but also progenitors and stem cells, even if in a very 
minor percentage. In order to compare bone marrow with similar distribution of blasts, only 
patients harboring blasts infiltration > 90% (more than 90% of the bone marrow are leukemic 
cells) were analyzed. To exclude false positive signals deriving from the not-leukemic 
population (progenitors and stem cells), stem cell were employed as undifferentiated control. 
As already demonstrated in chapter 3.1.3, the insulating loop doesn’t take place in the stem 
cell compartment in the mouse species; in this chapter the human counterpart was included 
for the same reason. Human stem cells were purchased by Lonza manufacture as CD133+ 
cells: CD133 (prominin-1) is a hematopoietic stem cells marker, even more stem cell specific 
than CD34, which is also present at progenitors stages; cells were expanded in vitro and 
CD34+ cells were collected. Mature monocytes were collected from blood after erythrolysis 
and lymphocytes depletion; they were chosen as control for the myeloid pathway; blood was 
friendly donated from healthy donors from our institute.  
 
 
Figure 33: Graphic representation of cell collection’s approach. In the upper lane AML bone marrow 
aspirates are depicted, in the lower blood sampling for healthy donors. At the side are illustrated the code colors 
reflecting different lineage. Both bone marrow and blood were treated to deplete not-myeloid lineage. Note that 
the percentage of blast is very high in bone marrow, but is not 100%: there could be some myeloid 
contamination, differentiated and not, or stem cells and progenitors. On the contrary the blood cell content from 
healthy humans after depletion of red blood cells and lymphocytes consists predominantly in circulating 
monocytes.  
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All collected samples were tested for two chromatin interactions, one insulating (+94 / 
promoter loop) and the other enhancing (URE / promoter loop) PU.1 gene by quantitative 3C; 
all samples underwent the initial controls as explained in chapter 3.1.3. Notably, the T cell 
specific loop, already detected in AML cell lines, took place also in primary AML blasts. 
Considering the variability of different acute myeloid leukemia, and also the heterogeneity of 
the leukemic population within the same patient, the distribution of all 11 analyzed samples 
was broad, as illustrated in Figure 34A, but strikingly higher than physiological cell types at 
earlier stages during hematopoietic development (stem cells,CD34+ cells) or later ones 
(mature myeloid cells). Since acute myeloid leukemia is characterized by a differentiation 
block during myeloid development, both these controls are required to state that the chromatin 
loop is not related to differentiation, but indeed only occurs in cancer situation. As additive 
control also the enhancing loop was investigated (Fig. 34B): as expected, mature myeloid 
cells harbor the highest frequency, CD34 cells the lowest level and AML blast an intermediate 
average within the patients. The reduction of the enhancing loop in AML blasts is 
significantly lower than the mature myeloid counterpart. Importantly, there is no correlation 
between the differentiation stage of leukemia subtypes and the insulating loop formation; for 
instance, 4 patients classified as M0-2 (undifferentiated blasts) harbored very different 
chromatin loop frequencies.  
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Figure 34: Insulating chromatin loop was found in AML blasts. q3C assay detecting in A) the insulating 
loop between +94 element and promoter and in B) the enhancing loop between the URE and the promoter. The 
first analyzed AML treated sample was set to 1 in both cases. 13 AML samples are displayed with different 
symbols for indicated subtype of leukemia (according to FAB classification). CD34+ cells were bought as 
CD133+, shortly expanded in vitro, and then collected for further analysis. My = myeloid cells, purified from 
blood sampling of healthy donors as mentioned in Figure 29. Horizontal bars represent S.D. for CD34 and 
S.E.M. for the other groups, where n > 5. In C) quantitative PCR was employed to assure that the chromosome 
11 at PU.1 locus was not duplicated or deleted. Genomic DNA was tested with three different primer pairs, two 
located in the PU.1 locus on human chromosome 11 and the third on chromosome 17. ΔCt was indicated as ratio 
between chr. 17 signal and each of the chr. 11 – PU.1 locus signal. Therefore the value 1 represent normal 
diploid context (2n, two alleles per gene). DNA was extracted from all samples, patients and donors. Error bars 
represent S.D. D,E) PU.1 levels were measured as fold over GAPDH by RealTime PCR on cDNA. While in D) 
three different populations are shown (P value between AML blasts and myeloid cells is >0,001), in E) the AML 
blasts were separated according to the loop formation entity in loophigh (n=5) or looplow (n=6) in respect with 
the mean in panel A). Horizontal bars represent the mean within each group.       
 
To exclude that the previous results were not artifacts due to macroscopic chromosomal 
aberrations (e.g. duplication of the PU.1 locus), copy number of PU.1 locus located on human 
chromosome 11 was compared to a random region on chromosome 17. Figure 34C shows that 
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all the patient samples as well as the healthy donors contained normal (2n) chromosome 
copies in the PU.1 locus. 
Next, to link PU.1 expression to the chromatin conformation of the locus, PU.1 transcript 
levels were measured (Figure 34D); as expected, mRNA differences between mature myeloid 
cells and more immature cells (both blast and CD34+) are statistically significant using t 
student method. But, dividing the AML samples in two groups according to the insulating 
loop frequency (loophigh and looplow), PU.1 mRNA didn’t significantly change (Figure 34E; 
p value = 0,148); however, in patients with high insulating loop frequency, PU.1 expression is 
downregulated more than in patients with less loop formation. More detailed statistical 
analysis with more patient samples are required to define whether the anti-correlation between 
loop and mRNA is significant. 
Last but not least, whenever the number of collected cells allowed to perform additional 
assays, CTCF binding and histone acetylation status at the promoter level were investigated. 
In Figure 35 illustrates the outcome with the first two analyzed patients. On the left a 
summary of previous q3C results is depicted, in order to show the chromatin conformation of 
the only two patients which could be processed also for ChIP. The patient 1# manifests a M4 
subtype of leukemia (acute myelomonocytic leukemia), whereas patient 9* a M0-2 (minimal 
differentiated acute myeloblast leukemia). Interestingly CTCF binds the PU.1 promoter in the 
AML which harbors the insulating loop and not viceversa; on the contrary, acetylation of 
H3K9 reflects the lack of the insulating loop. CD34+ cells were used as not differentiated but 
not leukemic cells: the PU.1 promoter is slightly acetylated and CTCF doesn’t bind. These 
initial but very promising results suggested again that the insulating loop is present not only in 
a specific lineage as T cells to silence PU.1, but this confirmation is also adopted in myeloid 
leukemic onset, where PU.1 gene is downregulated. 
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Figure 35: CTCF binding and histon acetylation was measured in two AML blasts and in CD34+ as 
negative control. On the right side the summary of the chromatin loops is illustrated and which samples were 
processed for ChIP assay. On the left enrichment of ChIP using CTCF and H3K9acetylated antibody is depicted 
as fold over IgG negative control. Values are indicated, error bars represent S.D.  
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4 Discussion 
4.1 A novel insulator regulates the PU.1 gene in T-cells 
The ETS-transcription factor PU.1 is a crucial lineage determinant in hematopoietic 
development. PU.1 is already expressed in hematopoietic stem cells at a sub-threshold low 
level, allowing a multilineage expression network. After reaching a critical threshold, for 
example by overexpression in myeloid pathway or downregulation during T-cell 
development, PU.1 determines commitment of multipotent progenitors to a specific lineage 
(Rosenbauer and Tenen, 2007; Burda et al., 2010). Thus, giving its crucial role in cell fate 
decision, its gene regulation has been intensively studied since its discovery (Klemsz et al., 
1990). However, many aspects of how PU.1 is differently regulated in different lineages 
remain an open question. One of this, and thus aim of this thesis, is to clarify how PU.1 gene 
is silenced during the T-cell lineage, which is a prerequisite of early thymic progenitors for 
correct progression of the multistep T cell differentiation (Rothenberg et al., 2008).  
4.1.1 Local high-order chromatin structure of the PU.1 gene in different 
hematopoietic lineages 
Cell-type PU.1 gene regulation is achieved by an orchestrated action of several discrete 
regulatory elements (Leddin et al., 2011; Zarnegar et al., 2010). However, up to now none of 
them could exhaustively explain PU.1 regulation in T-cells. So far, these regions were mainly 
identified based on two approaches: the evolutionary conservation of DNA sequences and 
chromatin structure features like histone modifications or DNA accessibility, interpolated by 
next generation sequencing coupled with either ChIP or DNase hypersensitivity (Wilson et 
al., 2011b; Zhang et al., 2012). Here, we chose a different approach to investigate uncovered 
layers of epigenetic regulation: the PU.1 promoter was screened for chromatin interactions in 
T-cells by genome-wide assay It is now a common perspective, that long-range interactions 
are directly involved in gene regulation, by which cis-acting elements can be recruited to their 
respective promoters (as enhancers, silencers or insulator, see 1.1.2). As shown in Table 3, 
intra-chromosomal interactions were detected with higher frequency (de and de, 2012), 
supporting the theory that most chromatin contacts occur within the same chromosome. It is 
worthwhile to notice, however, that also the inter-chromosomal interactions were differently 
located in T-cells (on chromosome 17) in respect to macrophages (chromosome 1), suggesting 
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that chromosomal territories are distributed in a cell-type specific fashion (Felsenfeld and 
Dekker, 2012). Importantly, we could confirm that the URE contacts the PU.1 promoter in 
macrophages, confirming by a genome-wide approach that this region is the dominant 
enhancer in the myeloid pathway (Ebralidze et al., 2008). MEF here served only as negative 
control: PU.1 expression is restricted within the hematopoietic system, therefore is absent in 
MEF. The fact that no interactions could be detected within the PU.1 locus in MEF suggested 
that in no hematopoietic cell type context PU.1 locus is most likely silenced by more global 
high-order epigenetic mechanisms, as the heterochromatin spreading. In this case the locus 
would be inaccessible for a proper digestion during the 3C assay, thus not forming any long-
range interactions. 
Next we analyzed the chromatin structure in committed cells in more detail, in which PU.1 is 
differently expressed: T-cells, B-cells and Macs representing low, intermediate and high level 
of PU.1, respectively. We further confirmed the putative chromatin interaction along the PU.1 
locus in a quantitative fashion by quantitative 3C (q3C), dissecting 100Kb around the PU.1 
gene body and analyzing also intermediate genomic location. As illustrated in Fig. 15, the 
local high-order chromatin structure of PU.1 reflects its differential expression, showing 
chromatin proximity of the URE and neighbor enhancers where PU.1 is expressed (Macs and 
B-cells), whereas the only interaction with the PU.1 promoter in T-cells involves the +71 
element. Only this interaction could be detected along the PU.1 locus, suggesting that the 
chromatin assume a loop conformation. 
PU.1 must be actively silenced in thymic progenitors, meaning that it has to be downregulated 
from a basal expression level in HSCs. Thus, to prove that the +71/PU.1 promoter loop is an 
active epigenetic mechanism, it is important to exclude its presence in more undifferentiated 
stages. Since early thymic progenitors are a rare population, the required number of cells for 
q3C could not be obtained. Here, we decided to take HSCs as multipotent cell population, 
which is even more undifferentiated than thymic progenitors. We only analyzed the two most 
prominent loops, the URE and the +71 with the promoter:indeed HSCs did not show high 
frequency of any above mentioned loops, supporting the idea that the loop observed in mature 
T-cells is established during differentiation. Curiously, in HSCs the loop formation was 
detected at basal level, while in MEF it was absent. It is therefore tempting to speculate that in 
the hematopoietic stem cell compartment PU.1 chromatin structure is bivalent, where both 
enhancing and repressing loop are present at basal level. It would be very interesting to 
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analyze the chromatin structure in CLPs (common lymphoid progenitors) as intermediate 
differentiation stage between HSCs and thymocytes. Taken into account that the PU.1 gene is 
transcribed at low level in HSCs, this suggests that not only histone modifications, but also 
chromatin conformation could determine the multilineage potential of a priming transcription 
factor. 
4.1.2 The +71 insulator silences PU.1 expression by chromatin looping 
In order to evaluate whether the PU.1 promoter-interacting DNA fragments have a functional 
role in PU.1 gene regulation, we performed in vitro reporter assay. We chose two regions 
which undergo intra-chromosomal interaction, locating both in proximity with the PU.1 
promoter (-25 Kb and +71 element respectively). Since our goal was to identify regulatory 
element of PU.1 gene in T-cells, we tested the above mentioned elements for insulating or 
repressive function. For that purpose we made use of the reporter assay previously established 
by Ishihara and colleagues (Ishihara et al., 2006). The -25Kb region was excluded from 
further investigation, because it couldn’t affect the luciferase transcription in the tested 
reporter assay; long-range interactions can in fact be just structural, hence chromatin 
interactions studies have always to be carefully interpretated and supported by functional 
assay (de and de, 2012; Splinter et al., 2006). The +71 element showed instead canonical 
properties of insulator, being position dependent but orientation independent. We therefore 
demonstrated that the +71 element is a potential enhancer blocking insulator (Bell et al., 
2001).  
The next question which arose was whether the +71 element represses PU.1 expression in 
vivo by chromatin looping. To address this crucial point, we first demonstrated that the 
chromatin interaction is DNA-sequence specific regardless the genomic context by making 
use of a transgenic mouse strain carrying the human PU.1 locus, but lacking the homologue 
region corresponding to the +71 element, in an endogenous PU.1KO background. Importantly, 
we have previously shown that the human counterpart can efficiently rescue the endogenous 
murine PU.1 loss in the hematopoietic system (Leddin et al., 2011). In this thesis, we were 
able to prove the murine +71 element to co-localize with the transgenic human PU.1 
promoter. Intriguingly, this finding indicates that both regulatory elements (+71 element and 
PU.1 promoter) are able to undergo interactive cross-binding irrespective of their genomic 
location, a phenomena which has been shown before for regulatory elements controlling 
expression of odorant receptor genes in neurons or expression of the interferon γ gene in 
91 
                                                              4 Discussion 
immune cells (Apostolou and Thanos, 2008; Lomvardas et al., 2006). Next, we generated 
transgenic T cell lines carrying exogenous copies of the PU.1 promoter, aiming to disrupt the 
endogenous loop by sequestering the insulator region by the transgenic promoter copies. First, 
we validated the system by detecting the long-range interaction between the endogenous 
insulator and the transgenic copies of the promoter. Then, we were able to detect a reduction 
of the endogenous loop, concomitantly with an increased PU.1 expression, thus demonstrating 
that the chromatin loop is responsible for maintaining the PU.1 locus silenced. By this assay 
we demonstrated the biological function of the chromatin loop as regulator of PU.1 
transcription. 
In conclusion, in a murine cell line context, a forced disruption of the endogenous loop is 
sufficient to de-repress the PU.1 gene. The increased transcription was demonstrated by a 
histone acetylation rise on the promoter as well as at transcript level.  
 
4.2 The +71 insulator function involves binding of chromatin 
organizers  
We discovered a novel insulator silencing PU.1 specifically in T-cells by chromatin looping. 
We next questioned which factors mediate this loop: several proteins are responsible to 
establish long-range interactions, determining a controlled high-order chromatin structure, at 
global level for spatial nuclear organization and at local level regulating gene expression. 
Within the insulator region the predicted binding sites of two of these chromatin organizer, 
CTCF and SatB1 (Galande et al., 2007; Phillips and Corces, 2009), were found and further 
confirmed by gel shift assay. Moreover, in vivo ChIP assay showed that both CTCF and 
SatB1 binding on the +71 element is restricted to T-cells.  
4.2.1 CTCF mediates the insulator function of the +71 element 
CTCF binding site is located within the insulator region, identified as core by luciferase 
reporter assay (see chapter 3.1.2). Thus, CTCF binding site was deleted in the construct 
employed in the enhancer blocking luciferase assay; the mutation of CTCF binding site led to 
a complete ablation of the repressing function on the luciferase gene, indicating that CTCF 
binding is necessary to confer to the +71 element the enhancer blocking insulating function. It 
is important to note that previously reported ChIP-seq experiments detected  high frequency 
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CTCF binding throughout the genome(Barski et al., 2007; Cuddapah et al., 2009; Jothi et al., 
2008; Kim et al., 2007; Schmidt et al., 2012b). It is an ongoing challenge in science to 
understand which binding sites have a direct function on gene-specific regulation and which 
are involved in maintaining the high order chromatin structure, sometimes being sufficient but 
not necessary. An striking example in this direction is represented by the ß-globin 
conformation locus during erythroid differentiation: the ß-globin gene must be induced, and 
CTCF was found to establish several differentiation-stage specific long-range interactions. 
Albeit many of them were altered upon loss of CTCF by knockout targeting, only few of them 
were responsible for the transcriptional regulation (Splinter et al., 2006).  
To investigate the biological function of CTCF in the insulation loop formation, we generated 
a CTCF inducible knock-down system in Jurkat cells. Here, we detected a reduction of the 
loop formation and a concomitant increase of histone acetalytion (H3K9ac) status on the PU.1 
promoter. H3K9ac is a hallmark of active transcription, but PU.1 transcript’s level remained 
invariant in kdCTCF lines. However, it is known that the PU.1 promoter is maintained in a 
silenced state by DNA methylation (Amaravadi and Klemsz, 1999); it had also been shown 
that the 5-AZA demethylating agent can de-repress PU.1 transcription by erasing its promoter 
methylation pattern. Taken this knowledge into account, we combined the downregulation of 
CTCF with the 5-AZA treatment, affecting in this way both chromatin looping and 
methylation of the PU.1 promoter. By this approach, PU.1 upregulation in kdCTCF lines was 
more profound, indicating that the epigenetic regulation is achieved by a coordination of 
different mechanism, as histone modification, chromatin conformation and DNA methylation. 
In conclusion, we showed that the loop formation is CTCF-dependent based on a loss-in-
function approach.  
It had been shown that CTCF binding can be methylation sensitive (Hark et al., 2000), 
however, CTCF is very versatile in accomplishing different roles, and the methylation 
inhibition on CTCF binding is not a universal feature: in fact, was mostly restricted to the 
sequences where CTCF plays a role in regulation of imprinted loci or during X inactivation 
(Ohlsson et al., 2010). Instead, in the two T-cell lines used in this thesis (EL-4 in chapter 3.1.3 
and Jurkat in chapter 3.2.2) this effect could not been observed for two main reasons. First, 
the insulating loop formation could occur in the physiological cellular context, where the 
PU.1 promoter region is methylated. Second, 5-AZA was sufficient for PU.1 derepression in 
both lines, and also necessary for Jurkat cells; on the other hand, the reduction of the 
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insulating loop was sufficient for PU.1 reactivation in EL-4, but not in Jurkat cells. Thus there 
is no direct correlation between methylation status of the promoter and CTCF occupancy. 
Third, treating EL-4 transgenic and mock cells with 5-AZA affected PU.1 expression, but not 
the entity of the loop disruption (data not shown). Taken together, our data strongly suggested 
that DNA methylation and CTCF-dependent long-range interactions are two independent 
mechanisms, whose cooperation result in a coordinated function on silencing PU.1 
expression.  
To gain new insights whether the CTCF mediation on this chromatin loop is dependent on 
direct binding of CTCF to the Pu.1 promoter, we used transgenic cell lines overexpressing the 
PU.1 promoter region. In this cellular context CTCF levels don’t vary, but the endogenous 
loop is reduced being sequestered by an exogenous promoter copy. This is the best model in 
our hands to determine the occupancy change of CTCF. Indeed, CTCF binding was decreased 
at endogenous promoter level, while remained invariant on the +71 insulator, which strongly 
correlates CTCF binding and loop formation. Therefore we suggest that an induced disruption 
of the endogenous insulating loop causes a shift in CTCF binding from the endogenous 
promoter to the exogenous one. 
Taken these findings together, we could demonstrate that CTCF directly mediates the 
insulating loop, which regulates PU.1 expression in a coordinated fashion with other 
epigenetic mechanism, as DNA methylation. 
4.2.2 SatB1 binds the +71 element but is not necessary for insulation 
activity 
The SatB1 binding site identified on the +71 element does not locate in the core region 
responsible for insulator function. However, taking into account that SatB1 is not that 
ubiquitous as CTCF, it was tempting to study whether CTCF and SatB1 could cooperate, and 
if so, whether this cooperation would confer T-cell specificity of PU.1 gene regulation. On the 
other hand, SatB1 was shown to bind the URE region in myeloid progenitors, mediating the 
respective enhancing function (Steidl et al., 2007). In conclusion, little is known about the 
role of SatB1 in gene regulation in hematopoiesis, motivating us to investigate the function of 
SatB1 T-cell specific binding in the PU.1 locus. Thus we first screened the perturbation of the 
insulating loop by applying the same approach as for CTCF.  
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Upon SatB1 downregulation, no significant changes were detected neither on PU.1 expression 
levels, nor on the histone acetylation, and the loop formation significantly increased. Hence, 
SatB1 is not responsible to directly repress PU.1 transcription. But these results are 
controversial to be analyzed: first, CTCF was upregulated, so the increasing of loop formation 
could be an indirect effect of the increased levels of CTCF; second, SatB1 down-regulation is 
necessary for T cell maturation, therefore our results could reflect a more mature status of 
PU.1 gene. All these open questions are intriguing, but they have not been investigated further 
in this thesis due to time constrains.  
4.3 AML blasts adopt the T-cell specific insulating loop 
conformation 
PU.1 aberrant expression is observed in different hematopoietic malignancies. PU.1 is 
overexpressed in erythroleukemia (Kosmieder 2005), its downregulation leads to AML in 
mouse models (DeKoter, 2006?, Rosenbauer, 2004); lack of silencing PU.1 causes T-ALL 
(Rosenbauer, 2006). Taken together, these studies performed on mouse models indicate that 
PU.1 role is dosage-dependent and lineage-specific not only as master lineage determinant in 
normal hematopoietic development, but also as tumor suppressor in leukemia. In human 
leukemia, point mutations are found in PU.1 promoter and gene body with very rare 
probability (Bonadies et al., 2011; Mueller et al., 2002); one SNP in the URE region could be 
involved in the leukemic progression of complex karyotype AMLs (Steidl, JCI 2007). Rather 
than mutations in the DNA sequence, PU.1 had been found to be blocked by other 
mechanisms: it is a target of oncogenic fusion protein in AML (AML1-ETO, Flt3-ITD, PML-
RARA) (Gilliland et al., 2004), PU.1 promoter acquires an aberrant methylation pattern in 
CML, especially evident during the blast crisis.  
It is clear that epigenetic plays a major role in gene regulation of master transcription factors 
as PU.1 in hematopoietic differentiation as well as in leukemia development. Therefore we 
investigated whether the T-cell specific conformation we identified in this thesis could also be 
present in the myeloid leukemic onset, where PU.1 is often downregulated. This hypothesis is 
based on the expression levels of PU.1, which are silenced both in mature thymocytes and 
myeloid blasts, respectively; this would reveal that the repressing loop between PU.1 
promoter and insulator is a specific mechanism of PU.1 gene regulation, occurring when PU.1 
transcription has to be inhibited. Here we show that AML (acute myeloid leukemia) cell lines 
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harbor the chromatin loop and CTCF occupancy at similar levels found in Jurkat, T-cell lines, 
suggesting that also in an AML context the insulating loop is CTCF-mediated. As control, 
two not hematopoietic lines were analyzed and don’t show neither the same conformation nor 
CTCF binding, suggesting, as for MEF in the mouse counterpart, that the PU.1 locus is here 
shut down likely by other more permanent epigenetic events, like heterochromatin spreading. 
To our knowledge, this is the first evidence of a long-range chromatin interaction, which can 
mark a specific gene for transcriptional silencing and can be adopted in an opposite lineage in 
a malignant context. 
4.3.1 The insulating loop is disrupted during differentiation of leukemic 
blasts 
To test the biological function of the insulating loop found in AML blast line, we decided to 
induce differentiation of these cells and observe the chromatin changes during this process. 
HL-60 cells derives from an APL-leukemia (acute promyelocytic leukemia), characterized by 
the t(15;17) translocation, causing the formation of the PML-RARα oncogene (Rizzo et al., 
1998), which traditionally correspond to the FAB subtype M3 (even if Dalton WT Jr and 
colleagues reporter in 1988 that HL-60 represent an M2 subtype, (Dalton, Jr. et al., 1988; 
Mueller et al., 2006a)). For our purpose, anyway, the detailed classification is not crucial, 
since we try here to identify a signature for AMLs unrelated to their differentiation stage; 
what was relevant for this thesis, is the property of HL-60 to be differentiated in mature 
monocytes upon phorbol ester (TPA) treatment. Thus HL-60 line represented a model to 
observe epigenetic changes when the cells escape from the leukemic program to establish a 
terminal differentiation cell fate. The chromatin conformation switched from a repressive 
state of PU.1, harboring the insulating loop, to an active state, marked by an increased loop 
with the URE enhancing region. This result strongly correlates with the previously analyzed 
populations in 3.1.3, confirming that within the same system PU.1 expression could be 
reflected by monitoring the two determinant loops of the PU.1 promoter, the insulating and 
the enhancing one. The current leading treatment of APL leukemia is all-trans retinoic acid 
(ATRA), which functions as the TPA by displacing the fusion protein PML-RARα from its 
targets. It had been shown that treating primary APL blast ex vivo with ATRA is sufficient to 
restore PU.1 expression and drive differentiation. Hence we speculate that one of the 
molecular mechanisms underlying this therapeutic effect could be the modulation of the long-
range interactions from the insulator to the URE enhancer. 
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4.3.2 PU.1 expression block is associated with the insulating loop in 
AML patients  
AML is a very heterogeneous disease, and different subtypes present drastically different 
prognostic prediction. The FAB classification was mainly based on morphological and 
cytochemical characteristic, integrating also genetic aberration such as chromosomal 
translocations. However, morphologic and genetic features don’t always correlate, or the 
molecular defects underlying cannot be identified. It is thus required to consider different 
levels to provide a more reliable classification, to close to gap between (epi)genome and 
phenotype. Current efforts are focusing on the application of genome-wide techniques to 
discovery new markers and tool for prognostication and prediction of response to therapy. In 
fact, apart from rare cases, such as PML-RARα in M3, where therapeutic drugs could be 
directed against one main oncogene, usually leukemia are treated by a combination of 
therapies, as allogenic bone marrow transplant and chemotherapy. Recently, epigenetic drugs 
are used in clinical treatment, as demethylating agents (citarabine) or inhibitors of histone 
deacetylase (for instance, tricostatin A), after astonishing results during the clinical trials 
(Estey, 2012a). It is therefore still challenging to investigate how genes are dysregulated and 
by which mechanisms, including epigenetic ones, can be involved in leukemogenesis.  
We therefore started to analyze primary AML blasts, asking whether the insulating loop we 
observed in vitro in an APL cell lines could also be detect in human patients. We collected 
blasts from 10 patients and compared them with 2 independent samples of CD34+ as 
undifferentiated progenitors and 5 samples of human myeloid cells, including monocytes and 
granulocytes. Intriguingly, the AML blasts assume the T-cell specific chromatin conformation 
in a wide distribution fashion. Notably, the loop formation doesn’t correlate with the FAB 
classification’s differentiation stage; in progenitors and mature myeloid cells, the loop was 
very low or absent, respectively. On the other hand, the levels of the PU.1/URE interaction 
anti-correlate with the insulating loop in AML patients; this difference is even more strikingly 
in mature monocytes, where the enhancing loop is very pronounced. We also confirmed that 
PU.1 transcripts is significantly lower than mature monocytes and is comparable to CD34+ 
cells, confirming a common knowledge of PU.1 expression in stem cells and overall leukemic 
blast (Zhu et al., 2012). The number of cells and of patients doesn’t allow us to perform 
statistically significant correlation studies between the chromatin loops and PU.1 expression. 
For the same reason CTCF occupancy and histone acetylation status of the PU.1 promoter 
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could have been investigated only in two patients, one harboring high levels and the other low 
ones of the insulating loop; the results of this pilot experiment again suggested the role of 
CTCF as mediator of the loop. On the other hand the acetylation status was inversed 
represented, indicating that the loop correlates with an inhibited state of transcription. 
However, taken in account the heterogeneity of the AMLs, these conclusions remain 
speculations due to limited number of the samples. 
In addition to limitations in collecting samples and in blast numbers obtained per patient, it is 
worthwhile to remind that the blasts must be considered heterogeneous (Dick, 2008) also 
within the same leukemia and that 3C analysis are performed on the whole population. 
Therefore these results, as every q3C outcome, have to be interpreted with particular care (de 
and de, 2012) when aiming of establishing a correlation between different chromatin 
conformations (here, the insulating and the enhancing loop): it is easy to compare loops levels 
in different populations when one of them doesn’t harbor them, like in the case of mature 
monocytes. Hence, it was possible to determine the threshold of the insulating loop to 0, and 
consequently to state that the levels in AML are consistently relevant. But the difficulty 
increases when samples present intermediate levels of loop formation, such as for the 
enhancing loop: here we could only assume that the basal level of this loop is represented by 
CD34+. Albeit these complications, by the analysis of two separate loops within the same 
locus, which often anti-correlating one to another, our results clearly demonstrated the 
coexistence of two opposite loops only in AML onset.  
In this thesis, the chromatin structure description aimed to enlighten another layer of PU.1 
gene regulation, therefore it would be interesting to quantify the association between local 
structure and PU.1 expression in AML onset and physiological one. In this perspective, it 
would be risky to correlate each loop with PU.1 expression; more informative would be 
instead, to first investigate statistically the relations between the two chromatin loops, for 
which we speculate in an anti-correlation, and subsequently associate the “local chromatin 
structure” score to the PU.1 transcript level. However, for such statistically based 
investigations the required number of samples should be incredibly higher. Moreover, the 
complicated PU.1 gene regulation and its dysregulation in leukemia can only be achieved by a 
coordination of several epigenetic mechanisms, as histone modification and DNA 
methylation. Anyway, these results demonstrated the need to include chromatin conformation 
studies in the epigenetic investigation. In fact, here we provide the first evidence how the 
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chromatin structure of PU.1 can assume in AML context the long-range interaction of an 
opposite lineage. 
4.4 A conclusive model 
The ETS-transcription factor PU.1 is one of the master driving differentiating gene in the 
hematopoietic system. PU.1 dynamic and lineage-specific expression underlies its versatility 
in lineage specification and cell fate decision; beyond that, a tight and coordinated 
transcriptional regulation is required. In this thesis we described an uncovered layer of PU.1 
gene regulation, the local chromatin structure. First, we identified a CTCF-dependent T-cell 
specific insulator, which contributes to inhibit PU.1 transcription during T-cell commitment 
and specification. Moreover we proposed that AML blasts silence PU.1 gene by mimicking 
the same chromatin loop, perturbing a myeloid-specific chromatin structure. 
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Figure 36: Local chromatin structure of the PU.1 gene in opposite hematopoietic lineages and its 
perturbation in AML condition. Schematic representation of the proposed role of chromatin conformation on 
PU.1 gene regulation: H3 states for not-acetylated-histone; CpG are known to be methylated and unmethylated 
in T cells and macrophages, respectively. In the AML situation are named undetermined, because of the 
heterogeneity of AML disease. We demonstrated that the loop is mediated by CTCF binding; however, it is not 
to be excluded, that other factors are involved, directly or indirectly. 
4.5  Perspectives 
In this thesis a novel molecular mechanism which regulates PU.1 silencing in T cells was 
identified; next, the hypothesis whether those could give new insight in PU.1 block in AML 
was investigated. These findings opened very important consequent questions. 
First of all, a subject for an ongoing project consists to validate the CTCF role for the 
insulating loop formation in AML lines. We therefore planned to apply the same approaches 
performed in T cell line also in AML context in vitro: insulating and enhancing PU.1 loops 
will be monitored upon knocking-down CTCF and by sequestering the endogenous loop by 
the mean of an exogenous PU.1 promoter. In both contexts DNA methylation contribution 
will be investigated by citarabine treatment. 
Moreover, it would be interesting to increase the number of primary AML patients, screening 
them for PU.1 locus long-range interaction, PU.1 expression levels and CTCF occupancy; by 
that, statistical approaches could be performed.  
The correlation of these studies could be potentially developed a novel platform to better 
define leukemia classification, therefore improving prognostic prediction and ad hoc 
therapies. As long term goal, the PU.1 gene could represent one reference gene for integrating 
current genome-wide associations (GWAs) studies with epigenetic signatures.  
Another aspect which was not conclusively investigated is the role of SatB1 in regulating the 
insulating loop is the speculating interplay between the chromatin organizers CTCF and 
SatB1. Their apparent opposite function in mediating and inhibiting the insulating loop leads 
to speculate on the relevance of the interplay between the two chromatin organizers, both at 
spatial nuclear architecture level and at local high-order chromatin structure. It would be very 
informative to then study the perturbation of such potential coordinated function in a 
neoplastic context. It had been shown that loss in function of CTCF can promote tumor 
progression (Witcher and Emerson, 2009), whereas it is suggested than an overexpression of 
SatB1 is associated with different malignancies, as some type of breast or colon cancer 
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(Kohwi-Shigematsu et al., 2012). But, their role in cancer remains elusive. In a preliminary 
study, we could show that CTCF and SatB1 co-occupy the insulator. Hence, it is fascinating 
to investigate whether they interact at protein or DNA level, and if so, if they cooperate in a 
synergistic, redundant or antagonist manner.  
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a.m. above mentioned 
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ATCC american tissue culture collection 
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BMMΦ bone marrow derived macrophages 
bp base pair 
BS binding site 
BSA bovine serum albumin 
CDS coding determining sequence 
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CMP common myeloid progenitor 
c-Myc myelocytomatosis viral oncogene homolog 
CTCF CCCTC-binding factor 
DBD DNA binding domain 
DMEM Dulbecco’s modified Eagle medium 
DMSO dimethylsulfoxid 
DNA desoxyribonucleic acid 
dNTP deoxynucleotide triphosphate 
DTT dithiotreitol 
ECL enzymatic chemiluminescence 
e.g. exempli gratia 
EDTA ethylenediaminetetraacetate 
Env  envelope protein 
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F forward 
FACS fluorescent activated cell sorting 
FCS fetal calf serum 
FITC fluoresceinisothiocyanat 
GMP granulocyte-macrophage precursor 
Gag-pol group antigen protein - polymerase 
GFP green-fluorescent protein 
h hour 
HCl hydrochloric acid 
HRP horseradish peroxidase 
HSC hematopoietic stem cell 
Ig immunoglobulin 
IgG immune globulin gamma 
Kb kilobase 
kDakilo Dalton 
KCl potassium chloride 
KH2PO4 potassium phosphate monobasic 
KO knock out 
kd knock down 
Lin lineage 
LSC leukemia stem cell 
m or mm mouse, murine 
M molar 
mg milligram 
MIG MSCV-IRES-GFP 
min minutes 
ml millilitre 
mM milli molar 
μg microgram 
μl microliter 
μM micromolar 
mRNA messenger ribonucleic acid 
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NLS nuclear localization sequence 
p probability value 
PAC phage artificial chromosome 
PBS phosphate buffered saline 
PcG polycomb group 
PCR polymerase-chain-reaction 
PFU Pyrococcus furiosus derived polymerase 
pH potentia hydrogenii 
PI propidium iodide 
Pol polymerase 
P/S penicillin/streptomycin 
R reverse 
RNA ribonucleic acid 
rpm rotations per minute 
RT room teperature 
RT-PCR reverse transcription real time polymerase chain reaction 
s.d. standard deviation 
SDS Sodiumdodecylsulfat 
Seq sequencing 
SEM standard deviation of the mean 
TAE Tris/acetate/EDTA buffer 
Taq Taqman DNA polymerase 
TE Tris/EDTA 
U units 
URC upstream regulatory cluster 
URE upstream regulatory element 
wt wild type 
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